

BH

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
2 May 2002 (02.05.2002)

PCT

(10) International Publication Number
WO 02/34721 A1(51) International Patent Classification⁷: C07D 231/54,
401/12, 409/12, A61K 31/416, A61P 35/00Wilmington, DE 19810 (US). YUE, Eddy, W.; 9 Altemus
Drive, Landenberg, PA 19350 (US).

(21) International Application Number: PCT/US00/28952

(74) Agent: DOLAN, Peter, L.; Du Pont Pharmaceuticals
Company, Legal Patent Records Center, 1007 Market
Street, Wilmington, DE 19898 (US).

(22) International Filing Date: 20 October 2000 (20.10.2000)

(25) Filing Language: English

(81) Designated States (*national*): AU, BR, CA, CN, CZ, EE,
HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI,
SK, TR, UA, VN, ZA.

(26) Publication Language: English

(71) Applicant: DU PONT PHARMACEUTICALS COM-
PANY [US/US]; Chestnut Run Plaza, 974 Centre Road,
Wilmington, DE 19805 (US).(84) Designated States (*regional*): Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE).

Published:

(72) Inventors: NUGIEL, David, A.; 8 Vanessa Court, Cherry
Hill, NJ 08003 (US). CARINI, David, J.; 1921 Julian
Road, Wilmington, DE 19803 (US). DI MEO, Susan,
V.; 406 Clayton Avenue, Wilmington, DE 19809 (US).
VIDWANS, Anup; 3120 Naamans Road, Apartment F-8,

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 02/34721 A1

(54) Title: ACYLSEMICARBAZIDES AND THEIR USE AS CYCLIN DEPENDENT KINASE (CDK) INHIBITORS

(57) Abstract: The present invention relates to the synthesis of a new class of indeno [1,2-c]pyrazol-4-ones of formula (I): that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-9 and their regulatory subunits known as cyclins A-H. The invention also provides a novel method of treating cancer or other proliferative disease by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative disease by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.

5

TITLE

ACYLSEMICARBAZIDES AND THEIR USE AS CYCLIN DEPENDENT KINASE (CDK) INHIBITORS

FIELD OF THE INVENTION

This invention relates generally to novel 5-substituted-indeno[1,2-c]pyrazol-4-ones which are useful as cyclin dependent kinase (cdk) inhibitors, pharmaceutical compositions comprising the same, kits and methods for using the same for treating proliferative diseases, and intermediates and processes for making the same.

15

BACKGROUND OF THE INVENTION

One of the most important and fundamental processes in biology is the division of cells mediated by the cell cycle. This process ensures the controlled production of subsequent generations of cells with defined biological function. It is a highly regulated phenomenon and responds to a diverse set of cellular signals both within the cell and from external sources. A complex network of tumor promoting and suppressing gene products are key components of this cellular signaling process. Over expression of the tumor promoting components or the subsequent loss of the tumor suppressing products will lead to unregulated cellular proliferation and the generation of tumors (Pardee, Science 246:603-608, 1989).

Cyclin dependent kinases (cdks) play a key role in regulating the cell cycle machinery. These complexes consist of two components: a catalytic subunit (the kinase) and a regulatory subunit (the cyclin). To date, nine kinase subunits (cdk 1-9) have been identified along with several regulatory subunits (cyclins A-H) (A.M. Senderowicz and E.A. Sausville Journal of the National Cancer Institute (2000), 92 (5), 376-387; S. Mani; C. Wang; K. Wu; R. Francis; R.

- 5 Pestell *Exp. Opin. Invest. Drugs* (2000) 9(8), 1849-1870;
Brizuela, Leonardo; Gyuris, Jenó; Mansuri, Muzammil, *Princ.*
Mol. Oncol. (2000), 197-236; Fry, David W.; Garrett,
Michelle *Curr. Opin. Oncol., Endocr. Metab. Invest. Drugs*
(2000), 2(1), 40-59).
- 10 Each kinase associates with a specific regulatory
partner and together make up the active catalytic moiety.
Each transition of the cell cycle is regulated by a
particular cdk complex: G1/S by cdk2/cyclin E, cdk4/cyclin
D1 and cdk6/cyclin D2; S/G2 by cdk2/cyclin A and cdk1/cyclin
15 A; G2/M by cdk1/B. The coordinated activity of these kinases
guides the individual cells through the replication process
and ensures the vitality of each subsequent generation
(Sherr, *Cell* 73:1059-1065, 1993; Draetta, *Trends Biochem.*
Sci. 15:378-382, 1990)
- 20 An increasing body of evidence has shown a link between
tumor development and cdk related malfunctions. Over
expression of the cyclin regulatory proteins and subsequent
kinase hyperactivity have been linked to several types of
cancers (Jiang, *Proc. Natl. Acad. Sci. USA* 90:9026-9030,
25 1993; Wang, *Nature* 343:555-557, 1990). More recently,
endogenous, highly specific protein inhibitors of cdks were
found to have a major affect on cellular proliferation (Kamb
et al, *Science* 264:436-440, 1994; Beach, *Nature* 336:701-704,
1993). These inhibitors include p16^{INK4} (an inhibitor of
30 cdk4/D1), p21^{CIP1} (a general cdk inhibitor), and p27^{KIP1} (a
specific cdk2/E inhibitor). A recent crystal structure of
p27 bound to cdk2/A revealed how these proteins effectively
inhibit the kinase activity through multiple interactions
with the cdk complex (Pavletich, *Nature* 382:325-331, 1996).
- 35 These proteins help to regulate the cell cycle through
specific interactions with their corresponding cdk
complexes. Cells deficient in these inhibitors are prone to
unregulated growth and tumor formation.

5 Protein kinases, in particular, CDK, play a role in
the regulation of cellular proliferation. Therefore, CDK
inhibitors could be useful in the treatment of cell
proliferative disorders such as cancer, familial
adenomatosis polyposis, neuro-fibromatosis, psoriasis,
10 fungal infections, endotoxic shock, trasplantaion rejection,
vascular smooth cell proliferation associated with
atherosclerosis, pulmonary fibrosis, arthritis
glomerulonephritis and post-surgical stenosis and restenosis
(U.S. Patent No. 6,114,365).

15 CDKs are also known to play a role in apoptosis.
Therefore CDK inhibitors, could be useful in the treatment
of useful of cancer; viral infections, for example,
herpevirus, poxvirus, Epstein-Barr virus, Sindbis virus and
adenovirus; prevention of AIDS development in HIV-infected
20 individuals; autoimmune diseases, for example, systemic
lupus, erythematosus, autoimmune mediated
glomerulonephritis, rheumatoid arthritis, psoriasis,
inflammatory bowel disease, and autoimmune diabetes
mellitus; neurodegenerative disorders, for example,
25 Alzheimer's disease, AIDS-related dementia, Parkinson's
disease, amyotrophic lateral sclerosis, retinitis
pigmentosa, spinal muscular atrophy and cerebellar
degeneration; myelodysplastic syndromes, aplastic anemia,
ischemic injury associated with myocardial infarctions,
30 stroke and reperfusion injury, arrhythmia, atherosclerosis,
toxin-induced or alcohol related liver diseases,
hematological diseases, for example, chronic anemia and
aplastic anemia; degenerative diseases of the
musculoskeletal system, for example, osteoporosis and
35 arthritis, aspirin-sensitive rhinosinusitis, cystic
fibrosis, multiple sclerosis, kidney diseases and cancer
pain (U.S. Patent No. 6,107,305).

It has also been discovered that some cyclin-dependent
kinase inhibitors can be used in combination therapy with
40 other anticancer agents. For example, the cytotoxic
activity of the cyclin-dependent kinase inhibitor,
flavopiridol, has been used with other anticancer agents in

5 cancer combination therapy. Cancer Research, 57, 3375 (1997).


Also, it has recently been disclosed that CDK inhibitors may be useful in the chemoprevention of cancer. Chemoprevention is defined as inhibiting the development of
10 invasive cancer by either blocking the initiating mutagenic event or by blocking the progression of pre-malignant cells that have already suffered an insult or inhibiting tumor relapse (U.S. Patent No. 6,107,305).

Furthermore, it has recently been discovered that cdk5
15 is involved in the phosphorylation of tau protein, and therefore CDK inhibitors may be useful in the treatment of Alzheimer's disease (J. Biochem., 117, 741-749, 1995).

This body of evidence has led to an intense search for small molecule inhibitors of the cdk family as an approach
20 to cancer chemotherapy. There are no known examples of molecules related to the current invention which describe 5-substituted-indeno[1,2-c]pyrazoles as cdk inhibitors. There is one case describing indeno[1,2-c]pyrazoles having anticancer activity. There are two other examples which
25 describe indeno[1,2-c]pyrazoles having unrelated utilities and structures.

A series of indeno[1,2-c]pyrazoles having anticancer activity are described in JP 60130521 and JP 62099361 with the following generic structure:


30



No substitution is claimed on the indenophenyl portion of the molecule and the molecules are not indicated to be cdk

5 inhibitors. In addition, we discovered that substitution at the 5-position was critical for cdk inhibitory activity.


A series of indeno[1,2-c]pyrazoles having herbicidal activity are described in GB 2223946 with the following generic structure:



10

wherein X_n is defined as halo, alkyl, haloalkyl, and haloalkoxy; $n = 0-2$. In addition, R_1 is defined as acyl and R_2 is defined as alkyl or cycloalkyl.

15 A series of 1-(6'-substituted-4'-methylquinol-2'-yl)-3-methylindeno[1,2-c]pyrazoles having CNS activity are described by Quraishi, Farmaco 44:753-8, 1989 with the following generic structure:



20

Compounds of this series are not considered to be part of the presently claimed invention.

25

SUMMARY OF THE INVENTION

The present invention describes a novel class of indeno[1,2-c]pyrazol-4-ones or pharmaceutically acceptable


5 salt forms thereof that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk 1-9 and their regulatory subunits known as cyclins A-H.

10 It is another object of this invention to provide a novel method of treating proliferative diseases associated with CDK activity by administering a therapeutically effective amount of one of the compounds of the invention or a pharmaceutically acceptable salt form thereof.

15 It is another object of this invention to provide a novel method of treating cancer associated with CDK activity by administering a therapeutically effective amount of one of the compounds of the invention or a pharmaceutically acceptable salt form thereof.

20 It is another object of this invention to provide a novel method of treating a proliferative disease, which comprises administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer treatments such as radiation therapy, chemotoxic or chemostatic agents.

25 These and other objectives have been achieved by the inventors' discovery that compounds of formula (I):



(I)


5 wherein R¹, R², R⁵ and X are defined below or
pharmaceutically acceptable salts thereof are cyclin
dependent kinase inhibitors.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

10 The invention pertains to novel cyclin dependent kinase
inhibitors (cdks) and specifically, but not exclusively, as
inhibitors of cdk/cyclin complexes. The inhibitors of this
invention are indeno[1,2-c]pyrazol-4-one analogs. Certain
analogues were selective for their activity against cdks and
15 their cyclin bound complexes and were less active against
other known serine/threonine kinases such as Protein Kinase
A (PKA) and Protein Kinase C (PKC).

As described herein, the inhibitors of this invention
are capable of inhibiting the cell-cycle machinery and
20 consequently would be useful in modulating cell-cycle
progression, which would ultimately control cell growth and
differentiation. Such compounds would be useful for treating
subjects having disorders associated with excessive cell
proliferation, such as the treatment of cancer, psoriasis,
25 immunological disorders involving unwanted leukocyte
proliferation, in the treatment of restinosis and other
smooth muscle cell disorders, and the like.

(1) The present invention, in a first embodiment, describes
30 a novel compound of formula (I):



5 X is O or S;

R^1 is $-NR^3R^{3a}$, $-CF_3$, C_{1-4} alkyl substituted with 1-3 R^4 , C_{5-10} alkyl substituted with 0-3 R^4 , $C_{2-C_{10}}$ alkenyl substituted with 0-3 R^4 , $C_{2-C_{10}}$ alkynyl substituted with 0-3 R^4 , $C_{3-C_{10}}$ carbocycle substituted with 0-5 R^6 ,
 10 or 5-10 membered heterocycle substituted with 0-3 R^6 ;
 provided that if R^1 is phenyl or benzyl, then R^1 is substituted with 1-5 R^6 ;

R^2 is H, C_{1-10} alkyl substituted with 0-3 R^7 , C_{2-10} alkenyl substituted with 0-3 R^7 , C_{2-10} alkynyl substituted with
 15 0-3 R^7 , $-CF_3$, C_{3-10} carbocycle substituted with 0-5 R^8 ,
 or 3-10 membered heterocycle substituted with 0-5 R^8 ;

R^3 and R^{3a} are independently selected from the group: H, C_{1-4} alkyl, phenyl and benzyl;

R^4 and R^7 are, at each occurrence, independently selected
 20 from the group: halo, $-CN$, NO_2 , $-NR^9R^{9a}$, $NR^9NR^{9a}R^{9b}$,
 $NR^9C(O)OR^{10}$, $NR^9C(O)R^{10}$, $=O$, OR^{10} , SR^{10} , $-CF_3$, COR^{10} ,
 CO_2R^{10} , $CONR^9R^{9a}$, $NHC(O)NR^9R^{9a}$, $NHC(S)NR^9R^{9a}$,
 $SO_2NR^9R^{9a}$, SO_2R^{10} , C_{3-10} carbocycle substituted with
 0-5 R^{11} , and 5-10 membered heterocycle substituted with
 25 0-3 R^{11} ;

R^5 is selected from the group: H, $-C(O)R^{12}$, $-C(O)OR^{12}$, C_{1-4} alkyl, phenyl and benzyl;

R^6 and R^8 are, at each occurrence, independently selected
 from the group: halo, $-CN$, NO_2 , C_{1-4} alkyl, C_{1-4}
 30 haloalkyl, $NR^{13}R^{13a}$, $NR^{13}NR^{13a}R^{13b}$, $NR^{13}C(O)OR^{14}$,
 $NR^{13}C(O)R^{14}$, $=O$, OR^{14} , SR^{14} , $-CF_3$, COR^{14} , CO_2R^{14} ,
 $CONR^{13}R^{13a}$, $NHC(O)NR^{13}R^{13a}$, $NHC(S)NR^{13}R^{13a}$,

- 5 $\text{SO}_2\text{NR}^{13}\text{R}^{13a}$, SO_2R^{14} , $\text{C}_3\text{-10}$ carbocycle substituted with
0-5 R^{15} , and 5-10 membered heterocycle substituted with
0-3 R^{15} , or when two R^{6s} or R^{8s} are attached to two
adjacent carbon atoms, the two R^{6s} or R^{8s} may combine
to form $-\text{OCH}_2\text{O}-$ or $-\text{OCH}_2\text{CH}_2\text{O}-$;
- 10 R^9 is, at each occurrence, independently selected from the
group: H, $-\text{C}(\text{O})\text{R}^{12}$, $-\text{C}(\text{O})\text{OR}^{12}$, $\text{C}_1\text{-4}$ alkyl, phenyl and
benzyl;
- R^{9b} is, at each occurrence, independently selected from the
group: H, $-\text{C}(\text{O})\text{R}^{12}$, $-\text{C}(\text{O})\text{OR}^{12}$, $\text{C}_1\text{-4}$ alkyl, phenyl and
15 benzyl; or
- R^9 and R^{9a} , together with the nitrogen atom to which they
are attached, form a heterocycle substituted with 0-3
 R^{16} ;
- R^{9a} is selected from the group: H, $\text{C}_1\text{-4}$ alkyl, phenyl and
20 benzyl;
- R^{10} , R^{14} , R^{17} are, at each occurrence, independently selected
from the group: H, $\text{C}_1\text{-4}$ alkyl, phenyl, benzyl;
- R^{11} is, at each occurrence, independently selected from the
group: halo, $-\text{CN}$, NO_2 , $\text{C}_1\text{-4}$ alkyl, $\text{C}_1\text{-4}$ haloalkyl,
25 $\text{NR}^{18}\text{R}^{18a}$, $\text{NR}^{18}\text{NR}^{18a}\text{R}^{18b}$, $\text{NR}^{18}\text{C}(\text{O})\text{OR}^{17}$, $\text{NR}^{18}\text{C}(\text{O})\text{R}^{17}$, $=\text{O}$,
 OR^{17} , SR^{17} , COR^{17} , CO_2R^{17} , $\text{CONR}^{18}\text{R}^{18a}$, $\text{NHC}(\text{O})\text{NR}^{18}\text{R}^{18a}$,
 $\text{NHC}(\text{S})\text{NR}^{18}\text{R}^{18a}$, $\text{SO}_2\text{NR}^{18}\text{R}^{18a}$, SO_2R^{17} , $\text{C}_3\text{-10}$ carbocycle
substituted with 0-5 R^{19} , and 5-10 membered heterocycle
substituted with 0-3 R^{19} ;

5 R¹³ is, at each occurrence, independently selected from the group: H, -C(O)R¹², -C(O)OR¹², C₁₋₄ alkyl, phenyl and benzyl;

R^{13a} is, at each occurrence, independently selected from the group: H, C₁₋₄ alkyl, phenyl and benzyl; or

10 R¹³ and R^{13a}, together with the nitrogen atom to which they are attached, form a heterocycle substituted with 0-3 R¹⁶;

R^{13b} is, at each occurrence, independently selected from the group: H, -C(O)R¹², -C(O)OR¹², C₁₋₄ alkyl, phenyl and
15 benzyl;

R¹⁵, R¹⁶ and R¹⁹ are, at each occurrence, independently selected from the group: halo, -CN, NO₂, C₁₋₄ alkyl, C₁₋₄ haloalkyl, NR²⁰R^{20a}, NR^{20b}NR²⁰R^{20a}, NR²⁰C(O)OR²¹, NR²⁰C(O)R²¹, =O, OR²¹, SR²¹, COR²¹, CO₂R²¹, CONR²⁰R^{20a},
20 NHC(O)NR²⁰R^{20a}, NHC(S)NR²⁰R^{20a}, SO₂NR²⁰R^{20a}, SO₂R²¹, or when two R¹⁵s, R¹⁶s or R¹⁹s are attached to two adjacent carbon atoms, the two R¹⁵s R¹⁶s or R¹⁹s may combine to form -OCH₂O- or -OCH₂CH₂O-;

R¹⁸ is, at each occurrence, independently selected from the
25 group: H, -C(O)R¹², -C(O)OR¹², C₁₋₄ alkyl, phenyl and benzyl;

R^{18a} is, at each occurrence, independently selected from the group: H, C₁₋₄ alkyl, phenyl and benzyl; or

R¹⁸ and R^{18a}, together with the nitrogen atom to which they
30 are attached, form a heterocycle substituted with 0-3 R¹⁹;

5 R^{18b} is, at each occurrence, independently selected from the
group: H, -C(O)R¹², -C(O)OR¹², C₁₋₄ alkyl, phenyl and
benzyl; or
R²⁰ is, at each occurrence, independently selected from the
group: H, -C(O)R¹², -C(O)OR¹², C₁₋₄ alkyl, phenyl and
10 benzyl;
R^{20a} is, at each occurrence, independently selected from the
group: H, C₁₋₄ alkyl, phenyl and benzyl;
R^{20b} is, at each occurrence, independently selected from the
group: H, -C(O)R¹², -C(O)OR¹², C₁₋₄ alkyl, phenyl and
15 benzyl; and
R¹² and R²¹ are, at each occurrence, independently selected
from the group: H, C₁₋₄ alkyl, phenyl, benzyl; or
a pharmaceutically acceptable salt form thereof, a
pharmaceutically acceptable prodrug form thereof, an N-oxide
20 form thereof, or a stereoisomer thereof.

(2) Another embodiment of the invention is a compound of
embodiment (1) wherein:

X is O or S;

25 R¹ is -NR³R^{3a}, -CF₃, C₁₋₄ alkyl substituted with 1-3 R⁴, C₂₋
C₄ alkenyl substituted with 0-3 R⁴, C₂₋₄ alkynyl
substituted with 0-3 R⁴, C₃₋₁₀ carbocycle substituted
with 0-5 R⁶, or 5-10 membered heterocycle substituted
with 0-3 R⁶.

30

(3) Another embodiment of the invention is a compound of
embodiment (1) wherein:

X is O or S;

5 R^1 is $-NR^3R^{3a}$, $-CF_3$, C1-C4 alkyl substituted with 1-3 R^4 ,
C2-C4 alkenyl substituted with 0-3 R^4 , C2-C4 alkynyl
substituted with 0-3 R^4 , C3-C6 carbocycle substituted
with 0-5 R^6 , or 5-7 membered heterocycle substituted
with 0-3 R^6 .

10

(4) Another embodiment of the invention is a compound of
embodiment (1) wherein:

R^1 is C3-C6 saturated carbocycle substituted with 0-5 R^6 , or
5-7 membered saturated heterocycle substituted with 0-3
15 R^6 .

(5) Another embodiment of the invention is a compound of
embodiment (1) wherein:

R^1 is C5-C6 partially saturated carbocycle substituted with
20 0-5 R^6 , or 5-7 membered partially saturated heterocycle
substituted with 0-3 R^6 .

(6) Another embodiment of the invention is a compound of
embodiment (1) wherein:

25 R^1 is phenyl substituted with 1-5 R^6 , naphthyl substituted
with 0-5 R^6 , or 5-6 membered aromatic heterocycle
substituted with 0-3 R^6 .

(7) Another embodiment of the invention is a compound of
30 embodiment (1) wherein:

R^1 is phenyl substituted with 1-3 R^6 , naphthyl substituted
with 0-3 R^6 , or 5-6 membered aromatic heterocycle
substituted with 0-3 R^6 .

5

(8) Another embodiment of the invention is a compound of embodiment (1) wherein:

R^1 is C₃-C₁₀ carbocycle substituted with 0-5 R^6 , or 5-10 membered heterocycle substituted with 0-3 R^6 ;

10 R^6 is, at each occurrence, independently selected from the group: halo, -CN, NO₂, C₁₋₄ alkyl, C₁₋₄ haloalkyl, NR¹³R^{13a}, NR¹³NR^{13a}R^{13b}, NR¹³C(O)OR¹⁴, NR¹³C(O)R¹⁴, =O, OR¹⁴, SR¹⁴, -CF₃, COR¹⁴, CO₂R¹⁴, CONR¹³R^{13a}, NHC(O)NR¹³R^{13a}, NHC(S)NR¹³R^{13a}, SO₂NR¹³R^{13a}, and
15 SO₂R¹⁴, or when two R^{6s} are attached to two adjacent carbon atoms, the two R^{6s} may combine to form -OCH₂O- or -OCH₂CH₂O-.

(9) Another embodiment of the invention is a compound of embodiment (1) wherein:

20 R^6 is, at each occurrence, independently selected from the group: halo, -CN, NO₂, C₁₋₄ alkyl, C₁₋₄ haloalkyl, NR¹³R^{13a}, NR¹³NR^{13a}R^{13b}, NR¹³C(O)OR¹⁴, NR¹³C(O)R¹⁴, =O, OR¹⁴, SR¹⁴, -CF₃, COR¹⁴, CO₂R¹⁴, CONR¹³R^{13a},
25 NHC(O)NR¹³R^{13a}, NHC(S)NR¹³R^{13a}, SO₂NR¹³R^{13a}, and SO₂R¹⁴, or when two R^{6s} are attached to two adjacent carbon atoms, the two R^{6s} may combine to form -OCH₂O- or -OCH₂CH₂O-;

R^{13} , R^{13a} and R^{13b} are, at each occurrence, independently
30 selected from the group: H, C₁₋₄ alkyl, phenyl and benzyl; and

5 R^{14} is, at each occurrence, independently selected from the group: H, C₁₋₄ alkyl, phenyl, and benzyl.

(10) Another embodiment of the invention is a compound of embodiment (1) wherein:

10 R^6 is independently at each occurrence selected from the group: halo, -CN, NO₂, C₁₋₄ alkyl, C₁₋₄ haloalkyl, NR¹³R^{13a}, NR¹³C(O)OR¹⁴, NR¹³C(O)R¹⁴, OR¹⁴, SR¹⁴, -CF₃, COR¹⁴, CO₂R¹⁴, CONR¹³R^{13a}, NHC(S)NR¹³R^{13a}, SO₂NR¹³R^{13a}, and SO₂R¹⁴;

15 R^{13} , R^{13a} and R^{13b} are each independently selected from the group: H or methyl; and

R^{14} is independently selected from the group: H, methyl, phenyl, and benzyl.

20 (11) Another embodiment of the invention is a compound of embodiment (1) wherein:

X is O or S;

R^1 is -NR³R^{3a}, -CF₃, C₁₋₄ alkyl substituted with 1-3 R^4 ;

25 R^4 is, at each occurrence, independently selected from the group: halo, -CN, NO₂, -NR⁹R^{9a}, NR⁹NR^{9a}R^{9b}, NR⁹C(O)OR¹⁰, NR⁹C(O)R¹⁰, =O, OR¹⁰, SR¹⁰, -CF₃, COR¹⁰, CO₂R¹⁰, CONR⁹R^{9a}, NHC(O)NR⁹R^{9a}, NHC(S)NR⁹R^{9a}, SO₂NR⁹R^{9a}, and SO₂R¹⁰;

30 R^9 is, at each occurrence, independently selected from the group: H, C₁₋₄ alkyl, phenyl and benzyl;

R^{9a} is, at each occurrence, independently selected from the group: H, C₁₋₄ alkyl, phenyl and benzyl;

- 5 R^{9b} is, at each occurrence, independently selected from the group: H, C₁₋₄ alkyl, phenyl and benzyl; or R^9 and R^{9a} , together with the nitrogen atom to which they are attached, form a 5-7 membered heterocycle substituted with 0-3 R^{16} ;
- 10 R^{16} is, at each occurrence, independently selected from the group consisting of: halo, -CN, NO₂, C₁₋₄ alkyl, C₁₋₄ haloalkyl, $NR^{20}R^{20a}$, $NR^{20b}NR^{20}R^{20a}$, $NR^{20}C(O)OR^{21}$, $NR^{20}C(O)R^{21}$, =O, OR²¹, SR²¹, COR²¹, CO₂R²¹, CONR²⁰R^{20a}, NHC(O)NR²⁰R^{20a}, NHC(S)NR²⁰R^{20a}, SO₂NR²⁰R^{20a}, and
- 15 SO₂R²¹; and R^{20} , R^{20a} , and R^{20b} are, at each occurrence, independently selected from the group: H, C₁₋₄ alkyl, phenyl and benzyl.
- 20 (12) Another embodiment of the invention is a compound of embodiment (1) wherein:
- X is O or S;
- R^1 is -NR³R^{3a}, -CF₃, C₁₋₄ alkyl substituted with 1-3 R^4 ;
- R^3 and R^{3a} are independently selected from the group: H,
- 25 methyl, phenyl and benzyl;
- R^4 is, at each occurrence, independently selected from the group: halo, -CN, NO₂, -NR⁹R^{9a}, NR⁹NR^{9a}R^{9b}, NR⁹C(O)OR¹⁰, NR⁹C(O)R¹⁰, =O, OR¹⁰, SR¹⁰, -CF₃, COR¹⁰, CO₂R¹⁰, CONR⁹R^{9a}, NHC(O)NR⁹R^{9a}, NHC(S)NR⁹R^{9a},
- 30 SO₂NR⁹R^{9a}, SO₂R¹⁰, C₃₋₁₀ carbocycle substituted with 0-5 R^{11} , and 5-10 membered heterocycle substituted with 0-3 R^{11} ;

5 R^9 is, at each occurrence, independently selected from the
group: H, C₁₋₄ alkyl, phenyl and benzyl;
 R^{9a} is, at each occurrence, independently selected from the
group: H, C₁₋₄ alkyl, phenyl and benzyl;
 R^{9b} is, at each occurrence, independently selected from the
10 group: H, C₁₋₄ alkyl, phenyl and benzyl;
 R^{10} is, at each occurrence, independently selected from the
group: H, C₁₋₄ alkyl, phenyl, benzyl; and
 R^{11} is, at each occurrence, independently selected from the
group consisting of: selected from the group: halo, -
15 CN, NO₂, C₁₋₄ alkyl, C₁₋₄ haloalkyl, $NR^{18}R^{18a}$,
 $NR^{18}NR^{18a}R^{18b}$, $NR^{18}C(O)OR^{17}$, $NR^{18}C(O)R^{17}$, =O, OR^{17} ,
 SR^{17} , COR^{17} , CO_2R^{17} , $CONR^{18}R^{18a}$, $NHC(O)NR^{18}R^{18a}$,
 $NHC(S)NR^{18}R^{18a}$, $SO_2NR^{18}R^{18a}$, SO_2R^{17} , C₃₋₁₀ carbocycle
substituted with 0-5 R^{19} , and 5-10 membered heterocycle
20 substituted with 0-3 R^{19} .

(13) Another embodiment of the invention is a compound of
embodiment (1) wherein:

R^2 is C₁₋₄ alkyl substituted with 0-3 R^7 , C₂₋₄ alkenyl
25 substituted with 0-3 R^7 , C₂₋₄ alkynyl substituted with
0-3 R^7 , -CF₃, C₃₋₆ carbocycle substituted with 0-5 R^8 ,
or 3-7 membered heterocycle substituted with 0-5 R^8 .

(14) Another embodiment of the invention is a compound of
30 embodiment (1) wherein:

5 R^2 is C_{1-4} alkyl substituted with 0-3 R^7 , C_{2-4} alkenyl substituted with 0-3 R^7 , C_{2-4} alkynyl substituted with 0-3 R^7 , $-CF_3$, C_{3-6} carbocycle substituted with 0-5 R^8 , or 5-7 membered heterocycle substituted with 0-5 R^8 .

10 (15) Another embodiment of the invention is a compound of embodiment (1) wherein:

R^2 is C_{3-6} saturated carbocycle substituted with 0-5 R^8 , or 5-7 membered saturated heterocycle substituted with 0-5 R^8 .

15

(16) Another embodiment of the invention is a compound of embodiment (1) wherein:

R^2 is C_{5-6} partially saturated carbocycle substituted with 0-5 R^8 , or 5-7 membered partially saturated heterocycle substituted with 0-5 R^8 .

20

(17) Another embodiment of the invention is a compound of embodiment (1) wherein:

25 R^2 is phenyl substituted with 0-5 R^8 , naphthyl substituted with 0-5 R^8 or or 5-6 membered aromatic heterocycle substituted with 0-5 R^8 .

(18) Another embodiment of the invention is a compound of embodiment (1) wherein:

30 R^2 is phenyl substituted with 0-3 R^8 , naphthyl substituted with 0-3 R^8 or or 5-6 membered aromatic heterocycle substituted with 0-3 R^8 .

5

(19) Another embodiment of the invention is a compound of embodiment (1) wherein:

R^2 is C_{3-6} carbocycle substituted with 0-5 R^8 , or 5-7 membered heterocycle substituted with 0-5 R^8 ;

10

R^8 is, at each occurrence, independently selected from the group: halo, -CN, NO_2 , C_{1-4} alkyl, C_{1-4} haloalkyl, $NR^{13}R^{13a}$, $NR^{13}NR^{13a}R^{13b}$, $NR^{13}C(O)OR^{14}$, $NR^{13}C(O)R^{14}$, =O, OR^{14} , SR^{14} , - CF_3 , COR^{14} , CO_2R^{14} , $CONR^{13}R^{13a}$, $NHC(O)NR^{13}R^{13a}$, $NHC(S)NR^{13}R^{13a}$, $SO_2NR^{13}R^{13a}$, and SO_2R^{14} , or when two R^{8s} are attached to two adjacent carbon atoms, the two R^{8s} may combine to form - OCH_2O - or - OCH_2CH_2O -; and

15

R^{13} , R^{13a} , and R^{13b} are, at each occurrence, independently selected from the group: H, C_{1-4} alkyl, phenyl and benzyl; or R^{13} and R^{13a} , together with the nitrogen atom to which they are attached, form a 5-7 membered heterocycle substituted with 0-3 R^{16} .

20

25

(20) Another embodiment of the invention is a compound of embodiment (1) wherein:

R^2 is C_{3-6} carbocycle substituted with 0-5 R^8 , or 5-7 membered heterocycle substituted with 0-5 R^8 ;

30

R^8 is, at each occurrence, independently selected from the group: halo, -CN, NO_2 , C_{1-4} alkyl, C_{1-4} haloalkyl, $NR^{13}R^{13a}$, $NR^{13}NR^{13a}R^{13b}$, $NR^{13}C(O)OR^{14}$, $NR^{13}C(O)R^{14}$, =O,

5 OR¹⁴, SR¹⁴, -CF₃, COR¹⁴, CO₂R¹⁴, CONR¹³R^{13a},
 NHC(O)NR¹³R^{13a}, NHC(S)NR¹³R^{13a}, SO₂NR¹³R^{13a}, SO₂R¹⁴,
 C₃₋₁₀ carbocycle substituted with 0-5 R¹⁵, and 5-10
 membered heterocycle substituted with 0-3 R¹⁵, or when
 two R^{8s} are attached to two adjacent carbon atoms, the
 10 two R^{8s} may combine to form -OCH₂O- or -OCH₂CH₂O-;
 R¹³ R^{13a}, and R^{13b} are, at each occurrence, independently
 selected from the group: H, C₁₋₄ alkyl, phenyl and
 benzyl; and
 R¹⁵ is, at each occurrence, independently selected from the
 15 group consisting of: halo, -CN, NO₂, C₁₋₄ alkyl, C₁₋₄
 haloalkyl, NR²⁰R^{20a}, NR^{20b}NR²⁰R^{20a}, NR²⁰C(O)OR²¹,
 NR²⁰C(O)R²¹, =O, OR²¹, SR²¹, COR²¹, CO₂R²¹, CONR²⁰R^{20a},
 NHC(O)NR²⁰R^{20a}, NHC(S)NR²⁰R^{20a}, SO₂NR²⁰R^{20a}, and
 SO₂R²¹, or when two R^{15s} are attached to two adjacent
 20 carbon atoms, the two R^{15s} may combine to form -OCH₂O-
 or -OCH₂CH₂O-.

A more preferred embodiment, is a compound according to
 any of embodiments (2) to (12) further comprising embodiment
 25 (13).

A more preferred embodiment, is a compound according to
 any of embodiments (2) to (12) further comprising embodiment
 (14).

A more preferred embodiment, is a compound according to
 30 any of embodiments (2) to (12) further comprising embodiment
 (15).

5 A more preferred embodiment, is a compound according to any of embodiments (2) to (12) further comprising embodiment (16).

 A more preferred embodiment, is a compound according to any of embodiments (2) to (12) further comprising embodiment
10 (17).

 A more preferred embodiment, is a compound according to any of embodiments (2) to (12) further comprising embodiment (18).

 A more preferred embodiment; is a compound according to
15 any of embodiments (2) to (12) further comprising embodiment (19).

 A more preferred embodiment, is a compound according to any of embodiments (2) to (12) further comprising embodiment (20).

20 In a most preferred embodiment, the compounds of formula (I) are selected from:

3-(4-methoxyphenyl)-5-(2-(3,5-dimethoxybenzoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

25

3-(4-methoxyphenyl)-5-(2-isonicotinoyl
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-nictinoylhydrazinecarbox
30 amido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-(3,4-dihydroxybenzoyl)hydrazine
carboxamido)indeno[1,2-c]pyrazol-4-one;

35 3-(4-methoxyphenyl)-5-(2-(4-hydroxybenzoyl)hydrazine
carboxamido)indeno[1,2-c]pyrazol-4-one;

5

3-(4-methoxyphenyl)-5-(2-(3-aminobenzoyl)hydrazine
carboxamido)indeno[1,2-c]pyrazol-4-one;

10

3-(4-methoxyphenyl)-5-(2-(4-aminobenzoyl)hydrazine
carboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-(2-aminobenzoyl)hydrazine
carboxamido)indeno[1,2-c]pyrazol-4-one;

15

3-(4-methoxyphenyl)-5-(2-(4-N,N-dimethylaminobenzoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-methoxybenzoylhydrazine
carboxamido)indeno[1,2-c]pyrazol-4-one;

20

3-(4-methoxyphenyl)-5-(2-(2-hydroxybenzoyl)hydrazine
carboxamido)indeno[1,2-c]pyrazol-4-one; and

25

3-(4-methoxyphenyl)-5-(2-(3,5-diaminobenzoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-(1-naphthoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

30

3-(4-methoxyphenyl)-5-(2-amido
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-phenylamido
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

35

- 5 3-(4-methoxyphenyl)-5-(2-(4-methylbenzoyl
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;
- 3-(4-methoxyphenyl)-5-(2-(2-naphthoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;
- 10 3-(4-methoxyphenyl)-5-(2-(3-(4-hydroxyphenyl)propionyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;
- 3-(4-methoxyphenyl)-5-(2-(4-methoxybenzoyl)
15 hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;
- 3-(4-methoxyphenyl)-5-(2-(3-nitrobenzoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;
- 20 3-(4-methoxyphenyl)-5-(2-(3-nitrobenzoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;
- 3-(4-methoxyphenyl)-5-(2-(2-thienoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;
- 25 3-(4-methoxyphenyl)-5-(2-(3-methylbenzoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;
- 3-(4-methoxyphenyl)-5-(2-(3-amino-4-hydroxybenzoyl)
30 hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;
- 3-(4-methoxyphenyl)-5-(2-(2,5-dichlorobenzoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;
- 35 3-(4-methoxyphenyl)-5-(2-(3,4-dihydroxybenzoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

5

3-(4-piperazinylphenyl)-5-(2-(nicotinoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-(4-methylpiperazinyl)phenyl)-5-(2-(nicotinoyl)
10 hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-(4-methylpiperazinyl)phenyl)-5-(2-(isonicotinoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

15 3-(4-piperazinylphenyl)-5-(2-(isonicotinoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one; and

3-(4-piperazinylphenyl)-5-(2-(3,5-dimethoxybenzoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one; or
20 a pharmaceutically acceptable salt form thereof, a
pharmaceutically acceptable prodrug form thereof, an N-oxide
form thereof, or a stereoisomer thereof.

Another embodiment of the present invention is a
25 pharmaceutical composition comprising: a pharmaceutically
acceptable carrier and a therapeutically effective amount of
a compound of formula (I).

Another embodiment of the present invention is a method
of treating a proliferative disease associated with CDK
30 activity comprising: administering to a host in need of
such treatment a therapeutically effective amount of a
compound of formula (I), or a pharmaceutically effective
salt form thereof.

Another embodiment of the present invention is a method
35 of treating a cell proliferative disease associated with CDK
activity in a patient, comprising administering to said
patient a pharmaceutically effective amount of a compound of

5 formula (I), wherein the proliferative diseases is selected from the group consisting of: Alzheimer's disease, viral infections, auto-immune diseases, fungal disease, cancer, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis
10 glomerulonephritis, neurodegenerative disorders and post-surgical stenosis and restenosis.

Another embodiment of the present invention is a method of treating cancer associated with CDK activity in a patient, comprising administering to said patient a
15 pharmaceutically effective amount of a compound of formula (I), wherein the cancer is selected from the group consisting of: carcinoma such as bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix,
20 thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell
25 lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and
30 peripheral nervous system, including astrocytoma, neuroblastoma, glioma and schwannomas; other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratocanthoma, thyroid follicular cancer and Kaposi's sarcoma.

35 Another embodiment of the present invention is a method of treating a disease associated with apoptosis in a patient, comprising administering to said patient a pharmaceutically effective amount of a compound of formula (I), wherein the disease associated with apoptosis is

5 selected from the group consisting of: cancer, viral
infections, autoimmune diseases and neurodegenerative
disorder.

Another embodiment of the present invention is a method
of inhibiting tumor angiogenesis and metastasis in a
10 patient, comprising administering to said patient a
pharmaceutically effective amount of a compound of formula
(I).

Another embodiment of the present invention is a method
of treating a disease associated with protein kinase
15 activity in a patient, comprising administering to said
patient a pharmaceutically effective amount of a compound of
formula (I), wherein the protein kinase is selected from the
group consisting of: e.g. protein kinase C, her2, raf1,
MEK1, MAP kinase, EGF receptor, PDGF receptor, IGF receptor,
20 PI3 kinase, weel kinase, Src, and Abl.

Another embodiment of the present invention is a method
of modulating the level of cellular RNA and DNA synthesis in
a patient, comprising administering to said patient a CDK
inhibitory effective amount of a compound of formula (I).

25 Another embodiment of the present invention is a method
of treating viral infections in a patient, comprising
administering to said patient a CDK inhibitory effective
amount of a compound of formula (I), wherein the viral
infections is selected from the group consisting of HIV,
30 human papilloma virus, herpesvirus, poxvirus, Epstein-Barr
virus, Sindbis virus and adenovirus.

Another embodiment of the present invention is a method
of chemopreventing cancer in a patient, comprising
administering to said patient a CDK inhibitory effective
35 amount of a compound of formula (I).

Another embodiment of the present invention is a method
of inhibiting CDK activity comprising combining an effective
amount of the compound of formula (I) with a composition
containing CDK.

5 Another embodiment of the present invention is a method of treating cancer associated with CDK activity in a patient, comprising administering to said patient a pharmaceutically effective amount of a compound of formula (I) in combination (administered together or sequentially)
10 with known anti-cancer treatments such as radiation therapy or with cytostatic or cytotoxic agents, such as for example, DNA interactive agents, such as cisplatin or doxorubicin; topoisomerase II inhibitors, such as etoposide; topoisomerase I inhibitors such as CPT-11 or topotecan;
15 tubulin interacting agents, such as paclitaxel, docetaxel or the epothilones; hormonal agents, such as tamoxifen; thymidilate synthase inhibitors, such as 5-fluorouracil; and anti-metabolites, such as methotrexate.

Another embodiment of the present invention is a method
20 treating proliferative diseases associated with CDK activity, in a patient, comprising administering to said patient a pharmaceutically effective amount of a compound of formula (I), in combination (administered together or sequentially) with known anti-proliferating agents selected
25 from the group consisting of: altretamine, busulfan, chlorambucil, cyclophosphamide, ifosfamide, mechlorethamine, melphalan, thiotepe, cladribine, fluorouracil, floxuridine, gemcitabine, thioguanine, pentostatin, methotrexate, 6-mercaptapurine, cytarabine, carmustine, lomustine,
30 streptozotocin, carboplatin, cisplatin, oxaliplatin, iproplatin, tetraplatin, lobaplatin, JM216, JM335, fludarabine, aminoglutethimide, flutamide, goserelin, leuprolide, megestrol acetate, cyproterone acetate, tamoxifen, anastrozole, bicalutamide, dexamethasone,
35 diethylstilbestrol, prednisone, bleomycin, dactinomycin, daunorubicin, doxorubicin, idarubicin, mitoxantrone, losoxantrone, mitomycin-c, plicamycin, paclitaxel, docetaxel, CPT-11, epothilones, topotecan, irinotecan, 9-amino camptothecan, 9-nitro camptothecan, GS-211, etoposide,

5 teniposide, vinblastine, vincristine, vinorelbine,
procarbazine, asparaginase, pegaspargase, methotrexate,
octreotide, and estramustine, hydroxyurea.

Another embodiment of the present invention is a method
of inhibiting CDK1 activity, comprising administering to a
10 patient in need thereof an effective CDK1 inhibitory amount
of a compound according to claim 1, or a pharmaceutically
acceptable salt or prodrug form thereof.

Another embodiment of the present invention is a method
of inhibiting CDK2 activity, comprising administering to a
15 patient in need thereof an effective CDK2 inhibitory amount
of a compound according to claim 1, or a pharmaceutically
acceptable salt or prodrug form thereof.

Another embodiment of the present invention is a method
of inhibiting CDK3 activity, comprising administering to a
20 patient in need thereof an effective CDK3 inhibitory amount
of a compound according to claim 1, or a pharmaceutically
acceptable salt or prodrug form thereof.

Another embodiment of the present invention is a method
of inhibiting CDK4 activity, comprising administering to a
25 patient in need thereof an effective CDK4 inhibitory amount
of a compound according to claim 1, or a pharmaceutically
acceptable salt or prodrug form thereof.

Another embodiment of the present invention is a method
of inhibiting CDK5 activity, comprising administering to a
30 patient in need thereof an effective CDK5 inhibitory amount
of a compound according to claim 1, or a pharmaceutically
acceptable salt or prodrug form thereof.

Another embodiment of the present invention is a method
of inhibiting CDK6 activity, comprising administering to a
35 patient in need thereof an effective CDK6 inhibitory amount
of a compound according to claim 1, or a pharmaceutically
acceptable salt or prodrug form thereof.

Another embodiment of the present invention is a method
of inhibiting CDK7 activity, comprising administering to a

5 patient in need thereof an effective CDK7 inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.

Another embodiment of the present invention is a method of inhibiting CDK8 activity, comprising administering to a
10 patient in need thereof an effective CDK8 inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.

Another embodiment of the present invention is a method of inhibiting CDK9 activity, comprising administering to a
15 patient in need thereof an effective CDK9 inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.

It is a further object of the invention to provide a pharmaceutical kit for combination treatment of
20 proliferative diseases associated with CDK activity, said kit comprising a plurality of separate containers, wherein at least one of said containers contains a compound of formula (I), and at least another of said containers contains one or more compounds selected from the group
25 consisting of altretamine, busulfan, chlorambucil, cyclophosphamide, ifosfamide, mechlorethamine, melphalan, thiotepa, cladribine, fluorouracil, floxuridine, gemcitabine, thioguanine, pentostatin, methotrexate, 6-mercaptapurine, cytarabine, carmustine, lomustine,
30 streptozotocin, carboplatin, cisplatin, oxaliplatin, iproplatin, tetraplatin, lobaplatin, JM216, JM335, fludarabine, aminoglutethimide, flutamide, goserelin, leuprolide, megestrol acetate, cyproterone acetate, tamoxifen, anastrozole, bicalutamide, dexamethasone,
35 diethylstilbestrol, prednisone, bleomycin, dactinomycin, daunorubicin, doxorubicin, idarubicin, mitoxantrone, losoxantrone, mitomycin-c, plicamycin, paclitaxel, docetaxel, CPT-11, epothilones, topotecan, irinotecan, 9-amino camptothecin, 9-nitro camptothecin, GS-211, etoposide,

5 teniposide, vinblastine, vincristine, vinorelbine,
procarbazine, asparaginase, pegaspargase, methotrexate,
octreotide, and estramustine, hydroxyurea, and said
containers optionally contain a pharmaceutical carrier.

10 It is a further object of the invention to provide a
method of treating a patient having a disorder associated
with excessive cell proliferation, comprising administering
to the patient a therapeutically effective amount of a
compound of formula (I), such that the excessive cell
proliferation in the patient is reduced.

15 It is appreciated that certain features of the
invention, which are, for clarity, described in the context
of separate embodiments, may also be provided in combination
in a single embodiment. Conversely, various features of
the invention which are, for brevity, described in the
20 context of a single embodiment, may also be provided
separately or in any suitable subcombination.

DETAILED DESCRIPTION OF THE INVENTION

25 As used above, and throughout the description of the
invention, the following terms, unless otherwise indicated,
shall be understood to have the following meanings:

Definitions

30 As used herein, the following terms and expressions
have the indicated meanings.

 The term "compounds of the invention", and equivalent
expressions, are meant to embrace compounds of the invention
as hereinbefore described i.e. compounds of formula (I),
which expression includes the prodrugs thereof, N-oxides
35 thereof, the pharmaceutically acceptable salts thereof, and
the solvates thereof, e.g. hydrates, where the context so
permits. Similarly, reference to intermediates, whether or
not they themselves are claimed, is meant to embrace their
salts, and solvates, where the context so permits.

5 The term "derivative" means a chemically modified
compound wherein the modification is considered routine by
the ordinary skilled chemist, such as an ester or an amide
of an acid, protecting groups, such as a benzyl group for an
alcohol or thiol, and tert-butoxycarbonyl group for an
10 amine.

 The term "effective amount" means an amount of a
compound/composition according to the present invention
effective in producing the desired therapeutic effect.

 The term "amine protecting group" means an easily
15 removable group which is known in the art to protect an
amino group against undesirable reaction during synthetic
procedures and to be selectively removable. The use of
amine protecting groups is well known in the art for
protecting groups against undesirable reactions during a
20 synthetic procedure and many such protecting groups are
known, for example, T.H. Greene and P.G.M. Wuts, Protective
Groups in Organic Synthesis, 2nd edition, John Wiley & Sons,
New York (1991), incorporated herein by reference.
Preferred amine protecting groups are acyl, including
25 formyl, acetyl, chloroacetyl, trichloroacetyl, o-
nitrophenylacetyl, o-nitrophenoxyacetyl, trifluoroacetyl,
acetoacetyl, 4-chlorobutyryl, isobutyryl, o-nitrocinnamoyl,
picolinoyl, acylisothiocyanate, aminocaproyl, benzoyl and
the like, and acyloxy including methoxycarbonyl, 9-
30 fluorenylmethoxycarbonyl, 2,2,2-trifluoroethoxycarbonyl, 2-
trimethylsilylethoxycarbonyl, vinyloxycarbonyl,
allyloxycarbonyl, t-butyloxycarbonyl (BOC), 1,1-
dimethylpropynyloxycarbonyl, benzyloxycarbonyl (CBZ), p-
nitrobenzyloxycarbonyl, 2,4-dichlorobenzyloxycarbonyl, and
35 the like.

 The term "acid labile amine protecting group" means an
amine protecting group as defined above which is readily
removed by treatment with acid while remaining relatively

5 stable to other reagents. A preferred acid labile amine protecting group is *tert*-butoxycarbonyl (BOC).

The term "hydrogenation labile amine protecting group" means an amine protecting group as defined above which is readily removed by hydrogenation while remaining relatively
10 stable to other reagents. A preferred hydrogenation labile amine protecting group is benzyloxycarbonyl (CBZ).

The term "hydrogenation labile acid protecting group" means an acid protecting group as defined above which is readily removed by hydrogenation while remaining relatively
15 stable to other reagents. A preferred hydrogenation labile acid protecting group is benzyl.

The term "analogue" means a compound which comprises a chemically modified form of a specific compound or class thereof, and which maintains the pharmaceutical and/or
20 pharmacological activities characteristic of said compound or class.

The term "patient" includes both human and other mammals.

The term "pharmaceutical composition" means a
25 composition comprising a compound of formula (I) and at least one component selected from the group comprising pharmaceutically acceptable carriers, diluents, adjuvants, excipients, or vehicles, such as preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents,
30 suspending agents, sweetening agents, flavoring agents, perfuming agents, antibacterial agents, antifungal agents, lubricating agents and dispensing agents, depending on the nature of the mode of administration and dosage forms. Examples of suspending agents include ethoxylated isostearyl
35 alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents,

5 for example, parabens, chlorobutanol, phenol, sorbic acid,
and the like. It may also be desirable to include isotonic
agents, for example sugars, sodium chloride and the like.
Prolonged absorption of the injectable pharmaceutical form
can be brought about by the use of agents delaying
10 absorption, for example, aluminum monostearate and gelatin.
Examples of suitable carriers, diluents, solvents or
vehicles include water, ethanol, polyols, suitable mixtures
thereof, vegetable oils (such as olive oil) and injectable
organic esters such as ethyl oleate. Examples of excipients
15 include lactose, milk sugar, sodium citrate, calcium
carbonate, dicalcium phosphate phosphate. Examples of
disintegrating agents include starch, alginic acids and
certain complex silicates. Examples of lubricants include
magnesium stearate, sodium lauryl sulphate, talc, as well as
20 high molecular weight polyethylene glycols.

The term "solvate" means a physical association of a
compound of this invention with one or more solvent
molecules. This physical association includes hydrogen
bonding. In certain instances the solvate will be capable
25 of isolation, for example when one or more solvent molecules
are incorporated in the crystal lattice of the crystalline
solid. "Solvate" encompasses both solution-phase and
isolable solvates. Exemplary solvates include hydrates,
ethanolates, methanolates, and the like.

30 The term "alkyl" is intended to include both branched
and straight-chain saturated aliphatic hydrocarbon groups
having the specified number of carbon atoms. Examples of
alkyl include, but are not limited to, methyl, ethyl, n-
propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and
35 s-pentyl. In addition, the term is intended to include both
unsubstituted and substituted alkyl groups, the latter
referring to alkyl moieties having one or more hydrogen
substituents replaced by, but not limited to halogen,
hydroxyl, carbonyl, alkoxy, ester, ether, cyano, phosphoryl,

5 amino, imino, amido, sulfhydryl, alkythio, thioester, sulfonyl, nitro, heterocyclo, aryl or heteroaryl. It will also be understood by those skilled in the art that the substituted moieties themselves can be substituted as well when appropriate.

10 The term "alkenyl" means an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched having about 2 to about 10 carbon atoms in the chain. Preferred alkenyl groups have 2 to about 8
15 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkenyl chain. Exemplary alkenyl groups include ethenyl, propenyl, *n*-butenyl, *i*-butenyl, 3-methylbut-2-enyl, *n*-pentenyl, heptenyl, octenyl, and
20 decenyl.

The term "alkynyl" means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which may be straight or branched having about 2 to about 10 carbon atoms in the chain. Preferred alkynyl groups have 2 to about 8
25 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkynyl chain. Exemplary alkynyl groups include ethynyl, propynyl, *n*-butynyl, 2-butynyl, 3-methylbutynyl, *n*-pentynyl, heptynyl, octynyl and decynyl.
30

The terms "halo" or "halogen" as used herein refer to fluoro, chloro, bromo and iodo. The term "aryl" is intended to mean an aromatic moiety containing the specified number of carbon atoms, such as, but not limited to phenyl, indanyl
35 or naphthyl. The terms "cycloalkyl" and "bicycloalkyl" are intended to mean any stable ring system, which may be saturated or partially unsaturated. Examples of such include, but are not limited to, cyclopropyl, cyclopentyl,

5 cyclohexyl, norbornyl, bicyclo[2.2.2]nonane, adamantly, or tetrahydronaphthyl (tetralin).

As used herein, "carbocycle" or "carbocyclic residue" is intended to mean any stable 3- to 7-membered monocyclic or bicyclic or 7- to 13-membered bicyclic or tricyclic, any
10 of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl,; [3.3.0]bicyclooctane, [4.3.0]bicyclononane,
15 [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin).

As used herein, the term "heterocycle" or "heterocyclic system" is intended to mean a stable 5- to 7- membered
20 monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic ring which is saturated partially unsaturated or unsaturated (aromatic), and which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, O and S and including any
25 bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable
30 structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. If specifically noted, a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the
35 heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than

5 1. As used herein, the term "aromatic heterocyclic system"
is intended to mean a stable 5- to 7- membered monocyclic or
bicyclic or 7- to 10-membered bicyclic heterocyclic aromatic
ring which consists of carbon atoms and from 1 to 4
heterotams independently selected from the group consisting
10 of N, O and S. It is preferred that the total number of S
and O atoms in the aromatic heterocycle is not more than 1.

Examples of heterocycles include, but are not limited
to, 1H-indazole, 2-pyrrolidonyl, 2H,6H-1,5,2-dithiazinyl,
2H-pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H-
15 quinolizinyl, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl,
benzimidazolyl, benzofuranyl, benzothiofuranyl,
benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl,
benztetrazolyl, benzisoxazolyl, benzisothiazolyl,
benzimidazalonyl, carbazolyl, 4aH-carbazolyl, b-carbolinyl,
20 chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl,
2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran,
furanyl, furazanyl, imidazolidinyl, imidazolinyl,
imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl,
indolyl, isobenzofuranyl, isochromanyl, isoindazolyl,
25 isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl,
isoxazolyl, morpholinyl, naphthyridinyl,
octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl,
1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl,
oxazolidinyl., oxazolyl, oxazolidinylperimidinyl,
30 phenanthridinyl, phenanthrolinyl, phenarsazinyl, phenazinyl,
phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl,
piperazinyl, piperidinyl, pteridinyl, piperidonyl,
4-piperidonyl, pteridinyl, purinyl, pyranyl, pyrazinyl,
pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl,
35 pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl,
pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl,

5 quinazolinyl, quinolinyl, 4H-quinoliziny, quinoxaliny, quinuclidiny, carbolinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-thiadiaziny, 1,2,3-thiadiazoly, 1,2,4-thiadiazoly, 1,2,5-thiadiazoly, 1,3,4-thiadiazoly, thianthrenyl, thiazoly, 10 thienyl, thienothiazoly, thienooxazoly, thienoimidazoly, thiophenyl, triazinyl, 1,2,3-triazoly, 1,2,4-triazoly, 1,2,5-triazoly, 1,3,4-triazoly, xanthenyl. Preferred heterocycles include, but are not limited to, pyridiny, furanyl, thienyl, pyrroly, pyrazoly, imidazoly, indoly, 15 benzimidazoly, 1H-indazoly, oxazolidiny, benzotriazoly, benzisoxazoly, oxindoly, benzoxazolinyl, or isatinoyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.

As used herein, "pharmaceutically acceptable salts" 20 refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic 25 salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such 30 conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, 35 citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-

5 acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic,
ethane disulfonic, oxalic, isethionic, and the like.

 The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical
10 methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate,
15 ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Company, Easton, PA, 1990, p. 1445, the disclosure of which is hereby incorporated by reference.

20 The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive
25 toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio.

 The term "Pharmaceutically acceptable prodrugs" as used herein means those prodrugs of the compounds useful
30 according to the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and
35 effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.

5 The term "Prodrugs", as the term is used herein, are intended to include any covalently bonded carriers which release an active parent drug of the present invention *in vivo* when such prodrug is administered to a mammalian subject. Since prodrugs are known to enhance numerous
10 desirable qualities of pharmaceuticals (i.e., solubility, bioavailability, manufacturing, etc.) the compounds of the present invention may be delivered in prodrug form. Thus, the present invention is intended to cover prodrugs of the presently claimed compounds, methods of delivering the same,
15 and compositions containing the same. Prodrugs of the present invention are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or *in vivo*, to the parent compound. The transformation *in vivo*
20 may be, for example, as the result of some metabolic process, such as chemical or enzymatic hydrolysis of a carboxylic, phosphoric or sulphate ester, or reduction or oxidation of a susceptible functionality. Prodrugs include compounds of the present invention wherein a hydroxy, amino,
25 or sulfhydryl group is bonded to any group that, when the prodrug of the present invention is administered to a mammalian subject, it cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively. Functional groups which may be rapidly transformed, by metabolic
30 cleavage, *in vivo* form a class of groups reactive with the carboxyl group of the compounds of this invention. They include, but are not limited to such groups as alkanoyl (such as acetyl, propionyl, butyryl, and the like), unsubstituted and substituted aroyl (such as benzoyl and
35 substituted benzoyl), alkoxycarbonyl (such as ethoxycarbonyl), trialkylsilyl (such as trimethyl- and triethylsilyl), monoesters formed with dicarboxylic acids (such as succinyl), and the like. Because of the ease with which the metabolically cleavable groups of the compounds

5 useful according to this invention are cleaved in vivo, the
compounds bearing such groups act as pro-drugs. The
compounds bearing the metabolically cleavable groups have
the advantage that they may exhibit improved bioavailability
as a result of enhanced solubility and/or rate of absorption
10 conferred upon the parent compound by virtue of the presence
of the metabolically cleavable group. A thorough discussion
of prodrugs is provided in the following: Design of
Prodrugs, H. Bundgaard, ed., Elsevier, 1985; Methods in
Enzymology, K. Widder et al, Ed., Academic Press, 42, p.309-
15 396, 1985; A Textbook of Drug Design and Development,
Krogsgaard-Larsen and H. Bundgaard, ed., Chapter 5; "Design
and Applications of Prodrugs" p.113-191, 1991; Advanced Drug
Delivery Reviews, H. Bundgard, 8, p.1-38, 1992; Journal of
Pharmaceutical Sciences, 77, p. 285, 1988; Chem. Pharm.
20 Bull., N. Nakeya et al, 32, p. 692, 1984; Pro-drugs as
Novel Delivery Systems, T. Higuchi and V. Stella, Vol. 14 of
the A.C.S. Symposium Series, and Bioreversible Carriers in
Drug Design, Edward B. Roche, ed., American Pharmaceutical
Association and Pergamon Press, 1987, which are incorporated
25 herein by reference.

"Substituted" is intended to indicate that one or more
hydrogens on the atom indicated in the expression using
"substituted" is replaced with a selection from the
indicated group(s), provided that the indicated atom's
30 normal valency is not exceeded, and that the substitution
results in a stable compound. When a substituent is keto
(i.e., =O) group, then 2 hydrogens on the atom are replaced.

The term "Treating" refers to:
(i) preventing a disease, disorder or condition from
35 occurring in an animal which may be predisposed to the
disease, disorder and/or condition but has not yet
been diagnosed as having it;

- 5 (ii) inhibiting the disease, disorder or condition, i.e.,
arresting its development; and
(iii) relieving the disease, disorder or condition, i.e.,
causing regression of the disease, disorder and/or
condition.

10 Preparation of Compounds of the Invention

It will be apparent to those skilled in the art that
certain compounds of formula (I) can exhibit isomerism, for
example geometrical isomerism, e.g., E or Z isomerism, and
optical isomerism, e.g., R or S configurations. Geometrical
15 isomers include the cis and trans forms of compounds of the
invention having alkenyl moieties. It is well known in the
art how to prepare optically active forms, such as by
resolution of racemic forms or by synthesis from optically
active starting materials. All chiral, diastereomeric,
20 racemic forms and all geometric isomeric forms of a
structure are intended, unless the specific stereochemistry
or isomer form is specifically indicated.

Such isomers can be separated from their mixtures, by
the application or adaptation of known methods, for example
25 chromatographic techniques and recrystallization techniques,
or they are separately prepared from the appropriate isomers
of their intermediates, for example by the application or
adaptation of methods described herein.

The compounds of the present invention are useful in
30 the form of the free base or acid or in the form of a
pharmaceutically acceptable salt thereof. All forms are
within the scope of the invention.

Where the compound of the present invention is
substituted with a basic moiety, acid addition salts are
35 formed and are simply a more convenient form for use; and in
practice, use of the salt form inherently amounts to use of
the free base form. The acids which can be used to prepare
the acid addition salts include preferably those which
produce, when combined with the free base, pharmaceutically

5 acceptable salts, that is, salts whose anions are non-toxic
to the patient in pharmaceutical doses of the salts, so that
the beneficial inhibitory effects on CDK inherent in the
free base are not vitiated by side effects ascribable to the
anions. Although pharmaceutically acceptable salts of said
10 basic compounds are preferred, all acid addition salts are
useful as sources of the free base form even if the
particular salt, per se, is desired only as an intermediate
product as, for example, when the salt is formed only for
purposes of purification, and identification, or when it is
15 used as intermediate in preparing a pharmaceutically
acceptable salt by ion exchange procedures.

According to a further feature of the invention, acid
addition salts of the compounds of this invention are
prepared by reaction of the free base with the appropriate
20 acid, by the application or adaptation of known methods.
For example, the acid addition salts of the compounds of
this invention are prepared either by dissolving the free
base in aqueous or aqueous-alcohol solution or other
suitable solvents containing the appropriate acid and
25 isolating the salt by evaporating the solution, or by
reacting the free base and acid in an organic solvent, in
which case the salt separates directly or can be obtained by
concentration of the solution.

The compounds of this invention can be regenerated from
30 their corresponding acid addition salts by the application
or adaptation of known methods. For example, parent
compounds of the invention can be regenerated from their
acid addition salts by treatment with an alkali, e.g.
aqueous sodium bicarbonate solution or aqueous ammonia
35 solution.

Where the compound of the invention is substituted with
an acidic moiety, base addition salts may be formed and are
simply a more convenient form for use; and in practice, use
of the salt form inherently amounts to use of the free acid

5 form. The bases which can be used to prepare the base
addition salts include preferably those which produce, when
combined with the free acid, pharmaceutically acceptable
salts, that is, salts whose cations are non-toxic to the
animal organism in pharmaceutical doses of the salts, so
10 that the beneficial inhibitory effects on CDK inherent in
the free acid are not vitiated by side effects ascribable to
the cations. Pharmaceutically acceptable salts, including
for example alkali and alkaline earth metal salts, within
the scope of the invention are those derived from the
15 following bases: sodium hydride, sodium hydroxide,
potassium hydroxide, calcium hydroxide, aluminum hydroxide,
lithium hydroxide, magnesium hydroxide, zinc hydroxide,
ammonia, ethylenediamine, N-methyl-glucamine, lysine,
arginine, ornithine, choline, N,N'-dibenzylethylenediamine,
20 chlorprocaine, diethanolamine, procaine,
N-benzylphenethylamine, diethylamine, piperazine,
tris(hydroxymethyl)-aminomethane, tetramethylammonium
hydroxide, and the like.

Metal salts of compounds of the present invention may
25 be obtained by contacting a hydride, hydroxide, carbonate or
similar reactive compound of the chosen metal in an aqueous
or organic solvent with the free acid form of the compound.
The aqueous solvent employed may be water or it may be a
mixture of water with an organic solvent, preferably an
30 alcohol such as methanol or ethanol, a ketone such as
acetone, an aliphatic ether such as tetrahydrofuran, or an
ester such as ethyl acetate. Such reactions are normally
conducted at ambient temperature but they may, if desired,
be conducted with heating.

35 Amine salts of compounds of the present invention may
be obtained by contacting an amine in an aqueous or organic
solvent with the free acid form of the compound. Suitable
aqueous solvents include water and mixtures of water with
alcohols such as methanol or ethanol, ethers such as

5 tetrahydrofuran, nitriles such as acetonitrile, or ketones such as acetone. Amino acid salts may be similarly prepared.

The compounds of this invention can be regenerated from their corresponding base addition salts by the application
10 or adaptation of known methods. For example, parent compounds of the invention can be regenerated from their base addition salts by treatment with an acid, e.g. hydrochloric acid.

Pharmaceutically acceptable salts also include
15 quaternary lower alkyl ammonium salts. The quaternary salts are prepared by the exhaustive alkylation of basic nitrogen atoms in compounds, including nonaromatic and aromatic basic nitrogen atoms, according to the invention, i.e., alkylating the non-bonded pair of electrons of the nitrogen moieties
20 with an alkylating agent such as methylhalide, particularly methyl iodide, or dimethyl sulfate. Quaternarization results in the nitrogen moiety becoming positively charged and having a negative counter ion associated therewith.

As will be self-evident to those skilled in the art,
25 some of the compounds of this invention do not form stable salts. However, acid addition salts are more likely to be formed by compounds of this invention having a nitrogen-containing heteroaryl group and/or wherein the compounds contain an amino group as a substituent. Preferable acid
30 addition salts of the compounds of the invention are those wherein there is not an acid labile group.


As well as being useful in themselves as active compounds, salts of compounds of the invention are useful for the purposes of purification of the compounds, for
35 example by exploitation of the solubility differences between the salts and the parent compounds, side products and/or starting materials by techniques well known to those skilled in the art.

5 Compounds according to the invention, for example,
starting materials, intermediates or products, are prepared
as described herein or by the application or adaptation of
known methods, by which is meant methods used heretofore or
described in the literature, for example those described by
10 R. C. Larock in Comprehensive Organic Transformations, VCH
publishers, 1989.

 In the reactions described hereinafter it may be
necessary to protect reactive functional groups, for example
hydroxy, amino, imino, thio or carboxy groups, where these
15 are desired in the final product, to avoid their unwanted
participation in the reactions. Conventional protecting
groups may be used in accordance with standard practice, for
examples see T.W. Green and P.G.M. Wuts in "Protective Groups
in Organic Chemistry" John Wiley and Sons, 1991; J. F. W.
20 McOmie in "Protective Groups in Organic Chemistry" Plenum
Press, 1973.

 Preferred methods of synthesizing the compounds of the
invention include, but are not limited to, those methods
described below. Each of the references cited below are
25 hereby incorporated herein by reference.

Scheme 1




An approach to preparing indeno[1,2-c]pyrazol-4-ones is presented in Scheme 1 and can be used to prepare compounds of the present invention. The nitro group of dimethyl 3-nitrophthalate was reduced to the amine using catalytic hydrogenation. The aniline was acylated using acetic anhydride and pyridine as a base. A mixture of the resulting acetamide 2 and an acetophenone were treated with a strong base in an appropriate solvent at elevated temperature to give the desired triketone 3. Additional means of preparing triketones are known to one skilled in the art as described in Kilgore et al, Industrial and Engineering Chemistry 34:494-497, 1946, the contents of which are hereby incorporated herein by reference. The triketone was treated with hydrazine at elevated temperature in an appropriate solvent to give the indeno[1,2-c]pyrazol-4-one ring system. Additional means of preparing indeno[1,2-c]pyrazol-4-ones are known to one skilled in the art as described in Lemke et al., J. Heterocyclic Chem. 19:1335-1340, 1982; Mosher and

5 Soeder, J. Heterocyclic Chem. 8:855-59, 1971; Hrniciar and
Svanygova Collect. Czech. Chem. Commun. 59:2734-40, 1994 the
contents of which are hereby incorporated herein by
reference. The amide was deacylated by heating with a strong
acid in an appropriate solvent to give aniline 4. Treating
10 the intermediate 5-aminoindeno[1,2-c]pyrazol-4-one (4) with
2-(trimethylsilyl) ethoxymethylmethyl chloride (SEMCl) and a
suitable base in an inert solvent under reflux gives the SEM
protected intermediate. The aniline is converted to the
carbamate 5 using methods known to those skilled in the art.
15 This intermediate is reacted with carbazates in DMSO at
elevated temperatures and then the SEM group is removed by
treating with acid in a polar protic solvent to give the
desired acylsemicarbazide-containing indenopyrazole analogs
6.

20

Scheme 2



5

Another method for preparing the triketones 3 of Scheme 1 employs the condensation of a 1,3-diketone 7 with 3-nitrophthalic anhydride as described in Rotberg and Oshkaya, Zh. Organ. Khim. 8:84-87, 1972; Zh. Organ. Khim. 9:2548-2550, 1973, the contents of which are hereby incorporated herein by reference. The 1,3-diketones, when not commercially available can be readily prepared by one skilled in the art by the acetylation or trifluoroacetylation of the requisite methyl ketone, $R^1\text{COCH}_3$.

Reduction of the nitro derivative to the aniline 8 can be accomplished in a variety of ways including catalytic hydrogenation, treatment with zinc or iron under acidic conditions, or treatment with other reducing agents such as sodium dithionite or stannous chloride. Acetylation of the aniline 8 provides the triketones 3.

20

5 Alternatively, the indeno[1,2-c]pyrazol-4-ones of this invention can be prepared as shown in Scheme 2. Exposure of aniline 8 to phenyl chloroformate or phenyl chlorothionoformate in the presence of base, followed by treatment of the intermediate with the appropriate
10 carbazate, provides either trione 9, a hydrazone of 9, or mixtures of 9 and its hydrazone. When 9 or its hydrazone is allowed to react with hydrazine as described above the pyrazoles 10 are obtained.


Other features of the invention will become apparent
15 during the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.

Examples

Abbreviations used in the Examples are defined as
20 follows: "°C" for degrees Celsius, "CIMS" for chemical ionization mass spectroscopy, "eq" for equivalent or equivalents, "g" for gram or grams, "h" for hour or hours, "mg" for milligram or milligrams, "mL" for milliliter or milliliters, "mmol" for millimolar, "M" for molar, "min" for
25 minute or minutes, "p-TsOH" for para-toluenesulphonic acid, "DMF" for dimethylformamide, and "TFA" for trifluoroacetic acid.

Example I

30 Preparation of 3-(4-methoxyphenyl)-5-(2-(3,5-dimethoxybenzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-
4-one



5

Step 1. Synthesis of 11 from 7.

The synthesis for the starting aniline is this example
 10 is described in WO 9954308 and is incorporated herein by
 reference. A suspension of aniline 7 (0.5 g, 1.7 mmol) in
 dioxane (10 mL) was treated with triethylamine (0.48 mL, 3.4
 mmol) in one portion at room temperature. Then 2-
 (trimethylsilyl) ethyloxy chloride (SEMCl) (0.48 mL, 2.6
 15 mmol) was added in one portion and the mixture heated to
 reflux for 2 h. The reaction was cooled, diluted with EtOAc
 (20 mL) washed with water (10 mL), dried (MgSO₄) and the
 solvent removed at reduced pressure. The residue was taken
 up in benzene (3 mL), applied to a plug of silica gel (10 g)
 20 and eluted with EtOAc/Hexane (1:3) until all the yellow
 color was washed from the silica gel plug. The solvent was
 evaporated and the residue taken on to the next step. This
 material was dissolved in dioxane (10 mL) and treated with
 K₂CO₃ (0.36 g, 2.6 mmol) in one portion. Then
 25 phenylchloroformate (0.27 mL, 2.23 mmol) was added in one
 portion and the reaction heated to 50 C for 2 h. The
 reaction was cooled and the solvent removed at reduced
 pressure. The residue was recrystallized from EtOH to give a

5 yellow solid (0.4 g, 43%). mp °C; CIMS m/e calculated for $C_{30}H_{32}N_3O_5Si$: 542.2111, found: 542.2101.

Step 2. Synthesis of Ex. I from 11.

Compound 11 (0.015 g, 0.03 mmol) in DMSO (0.2 mL) was
10 treated with 3,5-dimethoxyphenylcarbазate (0.008 g, 0.06
mmol) in one portion and heated to 80 C for 30 minutes. The
solvent was removed at reduced pressure heating to 65 C. The
residue was dissolved in EtOH (0.5 mL) and treated with 4N
HCl/dioxane (0.4 mL). The mixture was heated to 80 C for 20
15 minutes and then cooled. The desired product was filtered
and air dried (0.008g, 62%). mp >300 °C; CIMS m/e calculated
for $C_{27}H_{24}N_5O_6(M+H^+)$: 514.1727, found: 514.1777.

Example II

20 Preparation of 3-(4-methoxyphenyl)-5-(2-
isonicotinoylhydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example
I using 4-pyridylcarbазate as the starting material. mp 248
°C; CIMS m/e calculated for $C_{24}H_{19}N_6O_4(M+H^+)$: 455.1468,
25 found: 455.1400.

Example III

Preparation of 3-(4-methoxyphenyl)-5-(2-
nictinoylhydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

30 Prepared in a similar fashion as described for example
I using 3-pyridylcarbазate as the starting material. mp 227
°C; CIMS m/e calc'd for $C_{24}H_{19}N_6O_4(M+H^+)$: 455.1468, found:
455.1487.

35 Example IV

5 Preparation of 3-(4-methoxyphenyl)-5-(2-(3,4-dihydroxy
 benzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

 Prepared in a similar fashion as described for example
 I using 3,4-dihydroxyphenyl carbazate as the starting
 material. mp >300 °C; CIMS m/e calc'd for C₂₅H₂₀N₅O₆ (M+H⁺):
10 486.1414, found: 486.1497.

Example V

Preparation of 3-(4-methoxyphenyl)-5-(2-(4-hydroxy
 benzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

15 Prepared in a similar fashion as described for example
 I using 4-hydroxyphenyl carbazate as the starting material.
 mp 283 °C; CIMS m/e calc'd for C₂₅H₂₀N₅O₅ (M+H⁺): 470.1464,
 found: 470.1544.

20 Example VI

Preparation of 3-(4-methoxyphenyl)-5-(2-(3-
 aminobenzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

 Prepared in a similar fashion as described for example
 I using 3-aminophenyl carbazate as the starting material. mp
25 250 °C; CIMS m/e calc'd for C₂₅H₂₁N₆O₄ (M+H⁺): 469.1624,
 found: 469.1513.

Example VII

30 Preparation of 3-(4-methoxyphenyl)-5-(2-(4-
 aminobenzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

 Prepared in a similar fashion as described for example
 I using 4-aminophenyl carbazate as the starting material. mp
 247 °C; CIMS m/e calc'd for C₂₅H₂₁N₆O₄ (M+H⁺): 469.1624,
 found: 469.1528.

35

Example VIII

5 Preparation of 3-(4-methoxyphenyl)-5-(2-(2-aminobenzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using 2-aminophenyl carbazate as the starting material. mp 257 °C; CIMS m/e calc'd for C₂₅H₂₁N₆O₄ (M+H⁺): 469.1624, found: 469.1548;

Example IX

Preparation of 3-(4-methoxyphenyl)-5-(2-(4-N,N-dimethylamino benzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

15 Prepared in a similar fashion as described for example I using 4-N,N-dimethylaminophenyl carbazate as the starting material. mp 259 °C; CIMS m/e calc'd for C₂₇H₂₅N₆O₄ (M+H⁺): 497.1937, found: 497.1876.

20 Example X

Preparation of 3-(4-methoxyphenyl)-5-(2-methoxybenzoyl hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using 2-methoxyphenyl carbazate as the starting material. mp 269 °C; CIMS m/e calc'd for C₂₆H₂₂N₅O₅ (M+H⁺): 484.1621, found: 484.1613.

Example XI

30 Preparation of 3-(4-methoxyphenyl)-5-(2-(2-hydroxy benzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using 2-hydroxyphenyl carbazate as the starting material. mp 280 °C; CIMS m/e calc'd for C₂₅H₂₀N₅O₅ (M+H⁺): 470.1464, found: 470.1419.

35

Example XII

5 Preparation of 3-(4-methoxyphenyl)-5-(2-(3,5-diaminobenzoyl)
 hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using 3,5-diaminophenyl carbazate as the starting material. mp >300 °C; CIMS m/e calc'd for C₂₅H₂₂N₇O₄(M+H⁺):

10 484.1733, found: 484.1776.

Example XIII

Preparation of 3-(4-methoxyphenyl)-5-(2-(1-naphthoyl)
 hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

15 Prepared in a similar fashion as described for example I using 1-naphthhydrazide as the starting material. CIMS m/e calc'd for C₂₉H₂₂N₅O₄(M+H⁺): 504.1672, found: 504.1706.

Example XIV

20 Preparation of 3-(4-methoxyphenyl)-5-(2-amido
 hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using semicarbazide as the starting material. CIMS m/e calc'd for C₁₉H₁₇N₆O₄(M+H⁺): 393.1311, found: 393.1333.

25

Example XV

Preparation of 3-(4-methoxyphenyl)-5-(2-phenylamido
 hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

30 Prepared in a similar fashion as described for example I using 4-phenylsemicarbazide as the starting material. CIMS m/e calc'd for C₂₅H₂₁N₆O₄(M+H⁺): 469.1624, found: 469.1681.

Example XVI

5 Preparation of 3-(4-methoxyphenyl)-5-(2-(4-methylbenzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using 4-methylphenyl carbazate as the starting material.
10 CIMS m/e calc'd for $C_{26}H_{22}N_5O_4 (M+H^+)$: 468.1672, found: 468.1688.

Example XVII

15 Preparation of 3-(4-methoxyphenyl)-5-(2-(2-naphthoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using 2-naphthhadrazide as the starting material. CIMS m/e calc'd for $C_{29}H_{22}N_5O_4 (M+H^+)$: 504.1672, found: 504.1710.

20 Example XVIII

Preparation of 3-(4-methoxyphenyl)-5-(2-(3-(4-hydroxyphenyl)propionyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example
25 I using 4-hydroxyhydrocinamic acid hydrazide as the starting material. CIMS m/e calc'd for $C_{27}H_{24}N_5O_5 (M+H^+)$: 498.1777, found: 498.1711.

Example XIX

30 Preparation of 3-(4-methoxyphenyl)-5-(2-(4-methoxybenzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using 4-methoxybenzhydrazide as the starting material.
35 CIMS m/e calc'd for $C_{26}H_{22}N_5O_5 (M+H^+)$: 484.1621, found: 484.1600.

5

Example XX

Preparation of 3-(4-methoxyphenyl)-5-(2-(3-nitrobenzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using 3-nitrobenzhydrazide as the starting material. CIMS m/e calc'd for $C_{25}H_{19}N_6O_6(M+H^+)$: 499.1366, found: 499.1304.

Example XXI

Preparation of 3-(4-methoxyphenyl)-5-(2-(3-nitrobenzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using 3,4,5-trimethoxybenzhydrazide as the starting material. CIMS m/e calc'd for $C_{28}H_{26}N_5O_7(M+H^+)$: 544.1832, found: 544.1812.

20

Example XXII

Preparation of 3-(4-methoxyphenyl)-5-(2-(2-thienoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using 2-thenoic hydrazide as the starting material. CIMS m/e calc'd for $C_{23}H_{18}N_5O_4S(M+H^+)$: 460.1080, found: 460.1012.

25

Example XXIII

Preparation of 3-(4-methoxyphenyl)-5-(2-(3-methylbenzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

30

Prepared in a similar fashion as described for example I using 3-methylbenzoic acid hydrazide as the starting material. CIMS m/e calc'd for $C_{26}H_{22}N_5O_4(M+H^+)$: 468.1672, found: 468.1640.

35

5

Example XXV

Preparation of 3-(4-methoxyphenyl)-5-(2-(2,5-dichlorobenzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using 2,5-dichlorobenzoic acid hydrazide as the starting material. CIMS m/e calc'd for $C_{25}H_{18}N_5O_4Cl_2 (M+H^+)$: 522.0736, found: 522.0777.


Example XXVI

15 Preparation of 3-(4-methoxyphenyl)-5-(2-(3,4-dihydroxybenzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one

Prepared in a similar fashion as described for example I using 3,4-dihydroxybenzoic acid hydrazide as the starting material. CIMS m/e calc'd for $C_{25}H_{20}N_5O_6 (M+H^+)$: 486.1414, found: 486.1445.

Example XXVII

25 Preparation of 3-(4-piperazinylphenyl)-5-(2-(nicotinoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one



Step 1. Preparation of 12

To a suspension of 139g (680 mmol) of 4-piperazinoacetophenone in 700mL of tetrahydrofuran at 25°C was added slowly over 20 min. a solution of 157g (720 mmol) of di-tert-butyl dicarbonate in 300mL of tetrahydrofuran. The resulting mixture was refluxed for 15h. After cooling the mixture was filtered, and the filtrate was concentrated under vacuum to provide an off-white solid. This crude product was recrystallized from diethyl ether/hexane to

5 afford 192g of the 12 as a white solid. NMR (CDCl_3) δ 7.89 (d, 2 H, $J = 9$ Hz), 6.87 (d, 2 H, $J = 9$ Hz), 3.59 (m, 4 H), 3.33 (m, 4 H), 2.53 (s, 3 H), 1.49 (s, 9 H).

Step 2. Preparation of 13 from 12

10 To a solution of 192g (630 mmol) of 12 and 90mL (750 mmol) of ethyl trifluoroacetate in 1000 mL of tetrahydrofuran at 25 °C was added slowly over 15 min. 280 mL (750 mmol) of 21% sodium ethoxide in ethanol, and the resulting solution then was stirred at 25°C for 16 h. The
15 reaction mixture was diluted with 500mL of water, and to this mixture was added 45mL of acetic acid. The resulting precipitate was recovered by filtration. The solids were washed with diethyl ether/hexane and dried to furnish 236g of 13 as an orange solid. NMR (CDCl_3) δ 7.87 (d, 2 H, $J = 9$
20 Hz), 6.87 (d, 2 H, $J = 9$ Hz), 6.45 (s, 1 H), 3.60 (m, 4 H), 3.41 (m, 4 H), 1.48 (s, 9 H).

Step 3. Preparation of 14 from 13

A suspension of 117g (610 mmol) of 3-nitrophthalic
25 anhydride in 560mL of acetic anhydride was heated until the mixture became homogeneous, and the solution then was allowed to cool to room temperature. To this solution was added 236g (590 mmol) of 13. The resulting mixture was cooled to 0°C, and 165mL (1200 mmol) of triethylamine was
30 added slowly over 10 min. The mixture was allowed to warm to 25°C, was stirred at 25°C for 1h, and then was heated to 65°C for 0.5h. After cooling to room temperature, the reaction mixture was poured into a well-stirred solution of 1200mL of 1.0 N hydrochloric acid and 2000mL of ethanol. The
35 resulting precipitate was recovered by filtration, washed with ethanol, and dried to provide 140g of 14 as an orange solid. NMR (acetone- d_6) δ 8.34 (d, 2H, $J = 9$ Hz), 8.05 (m, 3H), 7.07 (d, 2H, $J = 9$ Hz), 3.59 (br s, 8H), 1.48 (s, 9H).

5

Step 4. Preparation of 15 from 14

To a solution of 12.00g (25 mmol) of 14 in 500mL of ethanol and 50mL of conc. ammonium hydroxide at 25°C was added 500mL of water, followed by 15.3g (88 mmol) of sodium dithionite. The resulting mixture was stirred at 25°C for 16h. The reaction mixture was filtered, and the filtrate was reduced to ~1/2 the original volume under vacuum. This solution was adjusted to pH 3 employing hydrochloric acid and then extracted with ethyl acetate. The combined extracts were washed with water and brine, dried over anhyd. sodium sulfate, filtered, and concentrated. The resulting solids were recrystallized from ethanol/water to provide 8.40g of 15 as a green solid. NMR (DMSO-d₆) δ 8.20 (d, 2H, J = 9 Hz), 7.44 (t, 1H, J = 8 Hz), 7.02 (d, 2H, J = 9 Hz), 6.96 (d, 1H, J = 8 Hz), 6.91 (d, 1H, J = 8 Hz), 6.70 (br s, 2H), 3.46 (br s, 8H), 1.43 (s, 9H).

Step 5. Preparation of 16 from 15

To a mixture of 7.05g (15.6 mmol) of 15, 8.67g (63 mmol) of potassium carbonate, 250mL of acetone at 25°C was added 2.40mL of phenyl chloroformate, and the resulting mixture was stirred at 25°C for 20h. The mixture was diluted with 500mL of water, adjusted to pH 3 employing hydrochloric acid, and extracted with ethyl acetate. The combined extracts were washed with water and brine, dried over anhyd. sodium sulfate, filtered, and dried. The crude product was recrystallized from ethanol/water to afford 6.32g of 16 as a dark yellow solid. Mass Spec: m/e = 582 (M-H)⁺.

Step 6. Preparation of 18 from 16

5 A solution of 0.57g (1.0 mmol) of 16 and 0.41g (3.0 mmol) of nicotinic acid hydrazide in 20mL of DMSO was stirred at 90°C for 2h. After cooling the solvent was removed under high vacuum to afford crude 17.


A solution of the crude 17, 0.10mL (2.0 mmol) of hydrazine hydrate, and 0.014g (0.2 mmol) of hydrazine hydrochloride in 20mL of ethanol was refluxed for 20h. While still at reflux the reaction mixture was diluted by dropwise addition of 10mL of water at a rate such that the refluxing of the solution was continuous. The mixture was allowed to cool to room temperature, and the resulting precipitate was recovered by filtration, washed with 95% ethanol, and dried to provide 0.25g of 18 as a yellow solid.

Step 7. Preparation of XXVII from 18

20 A solution of 0.25g (0.4 mmol) of 18 in 10mL of
trifluoroacetic acid was stirred at 25°C for 2h. The excess
trifluoroacetic acid was removed under vacuum, and the
residue was dissolved in 20mL of hot ethanol. After cooling,
the resulting precipitate was recovered by filtration under
25 nitrogen and then dried under vacuum to afford 0.16g of the
desired product as its trifluoroacetate salt. mp 232 °C;
CIMS m/e calc'd for C₂₇H₂₅N₈O₃ (M+H⁺): 509.2050, found:
509.2060.

30 Example XXVIII

Preparation of 3-(4-(4-methylpiperazinyl)phenyl)-5-(2-(nicotinoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one



To a solution of 0.16g (0.26 mmol) of XXVII in 15mL of methanol and 5mL of water at 25°C was added sequentially
 10 0.77g (9.5 mmol) of 37% aqueous formaldehyde, 0.32g (5.1 mmol) of sodium cyanoborohydride, and 3 drop of acetic acid. The resulting solution was stirred for 16h at 25°C. The solution was made acidic (pH<1) with conc. hydrochloric acid and was stirred for 20 min. until gas evolution ceased. The
 15 solution then was made basic (pH.13) with 50% aqueous sodium hydroxide solution. The mixture was stirred for 20 min, and then was adjusted to pH 9 with hydrochloric acid. The resulting precipitate was recovered by filtration, washed with 95% ethanol, and dried under vacuum. The yellow solid
 20 thus obtained was dissolved in 2mL of trifluoroacetic acid, and the solution was diluted with 10mL of hot anhydrous ethanol. Upon cooling a precipitate formed. This solid was recovered by filtration and dried under vacuum to afford 0.08g of the desired product as its trifluoroacetate salt.
 25 mp 238 °C; CIMS m/e calc'd for C₂₈H₂₇N₈O₃ (M+H⁺): 523.2206, found: 523.2210.

Example XXIX

Preparation of 3-(4-(4-methylpiperazinyl)phenyl)-5-(2-
 30 (isonicotinoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-
one

- 5 Prepared from example XXX in a similar fashion as described for example XXVIII. mp 240 °C; CIMS m/e calc'd for $C_{28}H_{27}N_8O_3(M+H^+)$: 523.2206, found: 523.2208.

Example XXX

- 10 Preparation of 3-(4-piperazinylphenyl)-5-(2-(isonicotinoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one


- Prepared in a similar fashion as described for example XXVII using isonicotinic acid hydrazide as the starting material. mp 232 °C; CIMS m/e calc'd for $C_{27}H_{25}N_8O_3(M+H^+)$: 509.2050, found: 509.2065.
- 15

Example XXXI

- Preparation of 3-(4-piperazinylphenyl)-5-(2-(3,5-dimethoxybenzoyl)hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one
- 20

- Prepared in a similar fashion as described for example XXVII using 3,5-dimethoxybenzoic hydrazide as the starting material. mp >300 °C; CIMS m/e calc'd for $C_{30}H_{30}N_7O_5(M+H^+)$: 568.2309, found: 568.2316.
- 25

5

Table 1

Example #	R ¹ -C(O)N(R ⁵)NH-	R ²	mass (M ⁺ H)	mp (°C)
I	3,5-dimethoxy C ₆ H ₃ C(O)NHNH-	4-MeOC ₆ H ₄ -	514	>300
II	4-pyridylC(O)NHNH-	4-MeOC ₆ H ₄ -	455	248
III	3-pyridylC(O)NHNH-	4-MeOC ₆ H ₄ -	455	227
IV	3,4-dihydroxy- C ₆ H ₃ C(O)NHNH-	4-MeOC ₆ H ₄ -	486	>300
V	4-hydroxy- C ₆ H ₄ C(O)NHNH-	4-MeOC ₆ H ₄ -	470	283
VI	3-amino-C ₆ H ₄ C(O)NHNH-	4-MeOC ₆ H ₄ -	469	250
VII	4-amino-C ₆ H ₄ C(O)NHNH-	4-MeOC ₆ H ₄ -	469	247
VIII	2-amino-C ₆ H ₄ C(O)NHNH-	4-MeOC ₆ H ₄ -	469	257
IX	4-N,N-dimethylamino- C ₆ H ₄ C(O)NHNH-	4-MeOC ₆ H ₄ -	497	259
X	2-MeO-C ₆ H ₄ C(O)NHNH-	4-MeOC ₆ H ₄ -	484	269
XI	2-OH-C ₆ H ₄ C(O)NHNH-	4-MeOC ₆ H ₄ -	470	280
XII	3,5-di-NH ₂ -C ₆ H ₃ C (O)NHNH-	4-MeOC ₆ H ₄ -	484	>300
XIII	1-naphthylC(O)NHNH-	4-MeOC ₆ H ₄ -	504	
XIV	H ₂ NC(O)NHNH-	4-MeOC ₆ H ₄ -	393	

XV	$\text{C}_6\text{H}_4\text{HNC}(\text{O})\text{NHNH}-$	$4-\text{MeOC}_6\text{H}_4-$	469	
XVI	$4-\text{Me}-\text{C}_6\text{H}_4\text{C}(\text{O})\text{NHNH}-$	$4-\text{MeOC}_6\text{H}_4-$	468	
XVII	$2\text{-naphthylC}(\text{O})\text{NHNH}-$	$4-\text{MeOC}_6\text{H}_4-$	504	
XVIII	$4-\text{OH}-$ $\text{C}_6\text{H}_4\text{CH}_2\text{CH}_2\text{C}(\text{O})\text{NHNH}-$	$4-\text{MeOC}_6\text{H}_4-$	498	
XIX	$4-\text{MeO}-\text{C}_6\text{H}_4\text{C}(\text{O})\text{NHNH}-$	$4-\text{MeOC}_6\text{H}_4-$	484	
XX	$2-\text{NO}_2-\text{C}_6\text{H}_4\text{C}(\text{O})\text{NHNH}-$	$4-\text{MeOC}_6\text{H}_4-$	499	
XXI	$3,4,5\text{-tri-MeO}-$ $\text{C}_6\text{H}_2\text{C}(\text{O})\text{NHNH}-$	$4-\text{MeOC}_6\text{H}_4-$	544	
XXII	$2\text{-thienylC}(\text{O})\text{NHNH}-$	$4-\text{MeOC}_6\text{H}_4-$	460	
XXIII	$3-\text{Me}-\text{C}_6\text{H}_4\text{C}(\text{O})\text{NHNH}-$	$4-\text{MeOC}_6\text{H}_4-$	468	
XXIV	$3-\text{NH}_2-4-\text{OH}-$ $\text{C}_6\text{H}_3\text{C}(\text{O})\text{NHNH}-$	$4-\text{MeOC}_6\text{H}_4-$	485	
XXV	$2,5\text{-di-Cl}-$ $\text{C}_6\text{H}_3\text{C}(\text{O})\text{NHNH}-$	$4-\text{MeOC}_6\text{H}_4-$	522	
XXVI	$3,4\text{-di-OH}-$ $\text{C}_6\text{H}_3\text{C}(\text{O})\text{NHNH}-$	$4-\text{MeOC}_6\text{H}_4-$	486	
XXVII	$3\text{-pyridylC}(\text{O})\text{NHNH}-$	4-piperazinyl C_6H_4-	509	232
XXVIII	$3\text{-pyridylC}(\text{O})\text{NHNH}-$	4-(4-Me- $\text{piperazinyl})$ C_6H_4-	523	238
XXIX	$4\text{-pyridylC}(\text{O})\text{NHNH}-$	4-(4-Me- $\text{piperazinyl})$ C_6H_4-	523	240
XXX	$4\text{-pyridylC}(\text{O})\text{NHNH}-$	4-piperazinyl C_6H_4-	509	232
XXXI	$3,5\text{-di-MeO}-$ $\text{C}_6\text{H}_3\text{C}(\text{O})\text{NHNH}-$	4-piperazinyl C_6H_4-	568	>300

5

The compounds useful according to the invention optionally are supplied as salts. Those salts which are pharmaceutically acceptable are of particular interest since they are useful in administering the foregoing compounds for
10 medical purposes. Salts which are not pharmaceutically acceptable are useful in manufacturing processes, for isolation and purification purposes, and in some instances, for use in separating stereoisomeric forms of the compounds of this invention. The latter is particularly true of amine
15 salts prepared from optically active amines.

Where the compound useful according to the invention contains a carboxy group, or a sufficiently acidic bioisostere, base addition salts may be formed and are simply a more convenient form for use; and in practice, use
20 of the salt form inherently amounts to use of the free acid form.

Also, where the compound useful according to the invention contains a basic group, or a sufficiently basic bioisostere, acid addition salts may be formed and are
25 simply a more convenient form for use; and in practice, use of the salt form inherently amounts to use of the free base form.

The foregoing compounds useful according to the invention may also be mixed another therapeutic compound to
30 form pharmaceutical compositions (with or without diluent or carrier) which, when administered, provide simultaneous administration of a combination of active ingredients resulting in the combination therapy of the invention.

While it is possible for the compounds useful according
35 to the invention to be administered alone it is preferably to present them as pharmaceutical compositions. The pharmaceutical compositions, both for veterinary and for human use, useful according to the present invention comprise at least one compound of the invention, as above

5 defined, together with one or more acceptable carriers therefor and optionally other therapeutic ingredients.

In certain preferred embodiments, active ingredients necessary in combination therapy may be combined in a single pharmaceutical composition for simultaneous administration.

10 The choice of vehicle and the content of active substance in the vehicle are generally determined in accordance with the solubility and chemical properties of the active compound, the particular mode of administration and the provisions to be observed in pharmaceutical
15 practice. For example, excipients such as lactose, sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silicates combined with lubricants such as magnesium stearate, sodium lauryl sulphate and talc may be
20 used for preparing tablets. To prepare a capsule, it is advantageous to use lactose and high molecular weight polyethylene glycols. When aqueous suspensions are used they can contain emulsifying agents or agents which facilitate suspension. Diluents such as sucrose, ethanol,
25 polyethylene glycol, propylene glycol, glycerol and chloroform or mixtures thereof may also be used.

The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the oily phase may comprise merely an emulsifier
30 (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include
35 both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make up the emulsifying wax, and the way together with the oil and fat make up the emulsifying ointment base which forms the oily dispersed phase of a cream formulation. Emulgents and emulsion stabilizers

5 suitable for use in the formulation of the present invention include Tween® 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.

10 If desired, the aqueous phase of the cream base may include, for example, a least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof. The topical formulations may
15 desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethyl sulphoxide and related analogue.

20 The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties. Thus the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-
25 isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required.
30 Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used. Solid compositions of may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high
35 molecular weight polyethylene glycols, and the like.

 The pharmaceutical compositions can be administered in a suitable formulation to humans and animals by topical or systemic administration, including oral, inhalational, rectal, nasal, buccal, sublingual, vaginal, parenteral

5 (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), intracisternal and intraperitoneal. It will be appreciated that the preferred route may vary with for example the condition of the recipient.

10 The formulations can be prepared in unit dosage form by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general the formulations are
15 prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

A tablet may be made by compression or moulding,
20 optionally with one or more accessory ingredients. Compressed tables may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface
25 active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compounds moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of
30 the active ingredient therein.

Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of the invention.

If desired, and for more effective distribution, the
35 compounds can be microencapsulated in, or attached to, a slow release or targeted delivery systems such as a biocompatible, biodegradable polymer matrices (e.g. poly(d,l-lactide co-glycolide)), liposomes, and microspheres and subcutaneously or intramuscularly injected by a

5 technique called subcutaneous or intramuscular depot to
provide continuous slow release of the compound(s) for a
period of 2 weeks or longer. The compounds may be
sterilized, for example, by filtration through a bacteria
retaining filter, or by incorporating sterilizing agents in
10 the form of sterile solid compositions which can be
dissolved in sterile water, or some other sterile injectable
medium immediately before use.

Actual dosage levels of active ingredient in the
compositions of the invention may be varied so as to obtain
15 an amount of active ingredient that is effective to obtain a
desired therapeutic response for a particular composition
and method of administration. The selected dosage level
therefore depends upon the desired therapeutic effect, on
the route of administration, on the desired duration of
20 treatment and other factors.

Total daily dose of the compounds useful according to
this invention administered to a host in single or divided
doses may be in amounts, for example, of from about 0.001 to
about 100 mg/kg body weight daily and preferably 0.01 to 10
25 mg/kg/day. Dosage unit compositions may contain such
amounts of such submultiples thereof as may be used to make
up the daily dose. It will be understood, however, that the
specific dose level for any particular patient will depend
upon a variety of factors including the body weight, general
30 health, sex, diet, time and route of administration, rates
of absorption and excretion, combination with other drugs
and the severity of the particular disease being treated.

The amount of each component administered is determined
by the attending clinicians taking into consideration the
35 etiology and severity of the disease, the patient's
condition and age, the potency of each component and other
factors.

The formulations may be presented in unit-dose or
multi-dose containers, for example sealed ampoules and vials

5 with elastomeric stoppers, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from
10 sterile powders, granules and tablets of the kind previously described.

Administration of a compound of the present invention in combination with additional therapeutic agents, may afford an efficacy advantage over the compounds and agents
15 alone, and may do so while permitting the use of lower doses of each. A lower dosage minimizes the potential of side effects, thereby providing an increased margin of safety. The combination of a compound of the present invention with such additional therapeutic agents is preferably a
20 synergistic combination. Synergy, as described for example by Chou and Talalay, Adv. Enzyme Regul. 22:27-55 (1984), occurs when the therapeutic effect of the compound and agent when administered in combination is greater than the additive effect of the either the compound or agent when
25 administered alone. In general, a synergistic effect is most clearly demonstrated at levels that are (therapeutically) sub-optimal for either the compound of the present invention or a known anti-proliferative agent alone, but which are highly efficacious in combination. Synergy can be in terms
30 of improved inhibitory response without substantial increases in toxicity over individual treatments alone, or some other beneficial effect of the combination compared with the individual components.

The compounds of the invention, their methods or
35 preparation and their biological activity will appear more clearly from the examination of the following examples which are presented as an illustration only and are not to be considered as limiting the invention in its scope.

5 Procedures for evaluating the biological activity of compounds or compositions according to the invention are carried out as described herein or by the application or adaptation of known procedures, by which is meant procedures used heretofore or as described in the literature.

10 UTILITY

Inhibition of Kinase/Cyclin Complex Enzymatic Activity

Several of the compounds disclosed in this invention were assayed for their inhibitory activity against cdk4/D1 and cdk2/E kinase complexes. Briefly, the in vitro assays
15 employ cell lysates from insect cells expressing either of the kinases and subsequently their corresponding regulatory units. The cdk2/cyclinE is purified from insect cells expressing His-tagged cdk2 and cyclin E. The cdk/cyclin lysate is combined in a microtitre-type plate along with a
20 kinase compatible buffer, ^{32}P -labeled ATP at a concentration of 50 mM, a GST-Rb fusion protein and the test compound at varying concentrations. The kinase reaction is allowed to proceed with the radiolabeled ATP, then effectively stopped by the addition of a large excess of EDTA and unlabeled ATP.
25 The GST-Rb labeled protein is sequestered on a GSH-Sepharose bead suspension, washed, resuspended in scintillant, and the ^{32}P activity detected in a scintillation counter. The compound concentration which inhibits 50% of the kinase activity was calculated for each compound. A compound was
30 considered active if its IC_{50} was found to be less than 1 μM .

Inhibition of HCT 116 Cancer Cell Proliferation

To test the cellular activity of several compounds disclosed in this invention, we examined the effect of these
35 compounds on cultured HCT116 cells and determined their effect on cell-cycle progression by the colorimetric

5 cytotoxicity test using sulforhodamine B (Skehan et al. J.
Natl. Cancer Inst. 82:1107-12, 1990). Briefly, HCT116 cells
are cultured in the presence of test compounds at increasing
concentrations. At selected time points, groups of cells are
fixed with trichloroacetic acid and stained with
10 sulforhodamine B (SRB). Unbound dye was removed by washing
and protein-bound dye was extracted for determination of
optical density. A compound was considered active if its
IC₅₀ was found to be less than 10 μ M.


5

CLAIMS

What is claimed is:

1. A compound of formula (I):

10



X is O or S;

R¹ is -NR³R³ᵃ, -CF₃, C₁-₄ alkyl substituted with 1-3 R⁴, C₅-
10 alkyl substituted with 0-3 R⁴, C₂-C₁₀ alkenyl

15 substituted with 0-3 R⁴, C₂-C₁₀ alkynyl substituted
with 0-3 R⁴, C₃-C₁₀ carbocycle substituted with 0-5 R⁶,
or 5-10 membered heterocycle substituted with 0-3 R⁶;

provided that if R¹ is phenyl or benzyl, then R¹ is
substituted with 1-5 R⁶;

20 R² is H, C₁-₁₀ alkyl substituted with 0-3 R⁷, C₂-₁₀ alkenyl
substituted with 0-3 R⁷, C₂-₁₀ alkynyl substituted with
0-3 R⁷, -CF₃, C₃-₁₀ carbocycle substituted with 0-5 R⁸,
or 3-10 membered heterocycle substituted with 0-5 R⁸;

R³ and R³ᵃ are independently selected from the group: H,
25 C₁-₄ alkyl, phenyl and benzyl;

R⁴ and R⁷ are, at each occurrence, independently selected
from the group: halo, -CN, NO₂, -NR⁹R⁹ᵃ, NR⁹NR⁹ᵃR⁹ᵇ,
NR⁹C(O)OR¹⁰, NR⁹C(O)R¹⁰, =O, OR¹⁰, SR¹⁰, -CF₃, COR¹⁰,

- 5 CO₂R¹⁰, CONR⁹R^{9a}, NHC(O)NR⁹R^{9a}, NHC(S)NR⁹R^{9a},
SO₂NR⁹R^{9a}, SO₂R¹⁰, C₃₋₁₀ carbocycle substituted with
0-5 R¹¹, and 5-10 membered heterocycle substituted with
0-3 R¹¹;
- 10 R⁵ is selected from the group: H, -C(O)R¹², -C(O)OR¹², C₁₋₄
alkyl, phenyl and benzyl;
- R⁶ and R⁸ are, at each occurrence, independently selected
from the group: halo, -CN, NO₂, C₁₋₄ alkyl, C₁₋₄
haloalkyl, NR¹³R^{13a}, NR¹³NR^{13a}R^{13b}, NR¹³C(O)OR¹⁴,
NR¹³C(O)R¹⁴, =O, OR¹⁴, SR¹⁴, -CF₃, COR¹⁴, CO₂R¹⁴,
15 CONR¹³R^{13a}, NHC(O)NR¹³R^{13a}, NHC(S)NR¹³R^{13a},
SO₂NR¹³R^{13a}, SO₂R¹⁴, C₃₋₁₀ carbocycle substituted with
0-5 R¹⁵, and 5-10 membered heterocycle substituted with
0-3 R¹⁵, or when two R^{6s} or R^{8s} are attached to two
adjacent carbon atoms, the two R^{6s} or R^{8s} may combine
20 to form -OCH₂O- or -OCH₂CH₂O-;
- R⁹ is, at each occurrence, independently selected from the
group: H, -C(O)R¹², -C(O)OR¹², C₁₋₄ alkyl, phenyl and
benzyl;
- R^{9b} is, at each occurrence, independently selected from the
25 group: H, -C(O)R¹², -C(O)OR¹², C₁₋₄ alkyl, phenyl and
benzyl; or
- R⁹ and R^{9a}, together with the nitrogen atom to which they
are attached, form a heterocycle substituted with 0-3
R¹⁶;
- 30 R^{9a} is selected from the group: H, C₁₋₄ alkyl, phenyl and
benzyl;

- 5 R^{10} , R^{14} , R^{17} are, at each occurrence, independently selected from the group: H, C₁₋₄ alkyl, phenyl, benzyl;
- R^{11} is, at each occurrence, independently selected from the group: halo, -CN, NO₂, C₁₋₄ alkyl, C₁₋₄ haloalkyl, NR¹⁸R^{18a}, NR¹⁸NR^{18a}R^{18b}, NR¹⁸C(O)OR¹⁷, NR¹⁸C(O)R¹⁷, =O, OR¹⁷, SR¹⁷, COR¹⁷, CO₂R¹⁷, CONR¹⁸R^{18a}, NHC(O)NR¹⁸R^{18a}, NHC(S)NR¹⁸R^{18a}, SO₂NR¹⁸R^{18a}, SO₂R¹⁷, C₃₋₁₀ carbocycle substituted with 0-5 R¹⁹, and 5-10 membered heterocycle substituted with 0-3 R¹⁹;
- 15 R^{13} is, at each occurrence, independently selected from the group: H, -C(O)R¹², -C(O)OR¹², C₁₋₄ alkyl, phenyl and benzyl;
- R^{13a} is, at each occurrence, independently selected from the group: H, C₁₋₄ alkyl, phenyl and benzyl; or
- R^{13} and R^{13a} , together with the nitrogen atom to which they are attached, form a heterocycle substituted with 0-3 R¹⁶;
- 20 R^{13b} is, at each occurrence, independently selected from the group: H, -C(O)R¹², -C(O)OR¹², C₁₋₄ alkyl, phenyl and benzyl;
- 25 R^{15} , R^{16} and R^{19} are, at each occurrence, independently selected from the group: halo, -CN, NO₂, C₁₋₄ alkyl, C₁₋₄ haloalkyl, NR²⁰R^{20a}, NR^{20b}NR²⁰R^{20a}, NR²⁰C(O)OR²¹, NR²⁰C(O)R²¹, =O, OR²¹, SR²¹, COR²¹, CO₂R²¹, CONR²⁰R^{20a}, NHC(O)NR²⁰R^{20a}, NHC(S)NR²⁰R^{20a}, SO₂NR²⁰R^{20a}, SO₂R²¹, or
- 30 when two R¹⁵s, R¹⁶s or R¹⁹s are attached to two adjacent

- 5 carbon atoms, the two R¹⁵s R¹⁶s or R¹⁹s may combine to form -OCH₂O- or -OCH₂CH₂O-;
- R¹⁸ is, at each occurrence, independently selected from the group: H, -C(O)R¹², -C(O)OR¹², C₁₋₄ alkyl, phenyl and benzyl;
- 10 R^{18a} is, at each occurrence, independently selected from the group: H, C₁₋₄ alkyl, phenyl and benzyl; or
- R¹⁸ and R^{18a}, together with the nitrogen atom to which they are attached, form a heterocycle substituted with 0-3 R¹⁹;
- 15 R^{18b} is, at each occurrence, independently selected from the group: H, -C(O)R¹², -C(O)OR¹², C₁₋₄ alkyl, phenyl and benzyl; or
- R²⁰ is, at each occurrence, independently selected from the group: H, -C(O)R¹², -C(O)OR¹², C₁₋₄ alkyl, phenyl and
- 20 benzyl;
- R^{20a} is, at each occurrence, independently selected from the group: H, C₁₋₄ alkyl, phenyl and benzyl;
- R^{20b} is, at each occurrence, independently selected from the group: H, -C(O)R¹², -C(O)OR¹², C₁₋₄ alkyl, phenyl and
- 25 benzyl; and
- R¹² and R²¹ are, at each occurrence, independently selected from the group: H, C₁₋₄ alkyl, phenyl, benzyl; or a pharmaceutically acceptable salt form thereof, a pharmaceutically acceptable prodrug form thereof, an N-
- 30 oxide form thereof, or a stereoisomer thereof.

2. A compound according to claim 1 wherein:

X is O or S;

5 R^1 is $-NR^3R^{3a}$, $-CF_3$, C1-C4 alkyl substituted with 1-3 R^4 , C2-C4 alkenyl substituted with 0-3 R^4 , C2-C4 alkynyl substituted with 0-3 R^4 , C3-C₁₀ carbocycle substituted with 0-5 R^6 , or 5-10 membered heterocycle substituted with 0-3 R^6 .

10

3. A compound according to claim 1 wherein:

X is O or S;

R^1 is $-NR^3R^{3a}$, $-CF_3$, C1-C4 alkyl substituted with 1-3 R^4 ,

C2-C4 alkenyl substituted with 0-3 R^4 , C2-C4 alkynyl

15 substituted with 0-3 R^4 , C3-C₆ carbocycle substituted with 0-5 R^6 , or 5-7 membered heterocycle substituted with 0-3 R^6 .

4. A compound according to claim 1 wherein:

20 R^1 is C3-C₆ saturated carbocycle substituted with 0-5 R^6 , or 5-7 membered saturated heterocycle substituted with 0-3 R^6 .

5. A compound according to claim 1 wherein:

25 R^1 is C5-C₆ partially saturated carbocycle substituted with 0-5 R^6 , or 5-7 membered partially saturated heterocycle substituted with 0-3 R^6 .

6. A compound according to claim 1 wherein:

30 R^1 is phenyl substituted with 1-5 R^6 , naphthyl substituted with 0-5 R^6 , or 5-6 membered aromatic heterocycle substituted with 0-3 R^6 .

5

7. A compound according to claim 1 wherein:

R^1 is phenyl substituted with 1-3 R^6 , naphthyl substituted with 0-3 R^6 , or 5-6 membered aromatic heterocycle substituted with 0-3 R^6 .

10

8. A compound according to claim 1 wherein:

R^1 is C_3 - C_{10} carbocycle substituted with 0-5 R^6 , or 5-10 membered heterocycle substituted with 0-3 R^6 ;

R^6 is, at each occurrence, independently selected from the group: halo, -CN, NO_2 , C_{1-4} alkyl, C_{1-4} haloalkyl, $NR^{13}R^{13a}$, $NR^{13}NR^{13a}R^{13b}$, $NR^{13}C(O)OR^{14}$, $NR^{13}C(O)R^{14}$, =O, OR^{14} , SR^{14} , -CF₃, COR^{14} , CO_2R^{14} , $CONR^{13}R^{13a}$, $NHC(O)NR^{13}R^{13a}$, $NHC(S)NR^{13}R^{13a}$, $SO_2NR^{13}R^{13a}$, and SO_2R^{14} , or when two R^{6s} are attached to two adjacent carbon atoms, the two R^{6s} may combine to form -OCH₂O- or -OCH₂CH₂O-.

20

9. A compound according to claim 1 wherein:

R^6 is, at each occurrence, independently selected from the group: halo, -CN, NO_2 , C_{1-4} alkyl, C_{1-4} haloalkyl, $NR^{13}R^{13a}$, $NR^{13}NR^{13a}R^{13b}$, $NR^{13}C(O)OR^{14}$, $NR^{13}C(O)R^{14}$, =O, OR^{14} , SR^{14} , -CF₃, COR^{14} , CO_2R^{14} , $CONR^{13}R^{13a}$, $NHC(O)NR^{13}R^{13a}$, $NHC(S)NR^{13}R^{13a}$, $SO_2NR^{13}R^{13a}$, and SO_2R^{14} , or when two R^{6s} are attached to two adjacent carbon atoms, the two R^{6s} may combine to form -OCH₂O- or -OCH₂CH₂O-;

25

30

5 R¹³, R^{13a} and R^{13b} are, at each occurrence, independently selected from the group: H, C₁₋₄ alkyl, phenyl and benzyl; and

R¹⁴ is, at each occurrence, independently selected from the group: H, C₁₋₄ alkyl, phenyl, and benzyl.

10

10. A compound according to claim 1 wherein:

R⁶ is independently at each occurrence selected from the group: halo, -CN, NO₂, C₁₋₄ alkyl, C₁₋₄ haloalkyl, NR¹³R^{13a}, NR¹³C(O)OR¹⁴, NR¹³C(O)R¹⁴, OR¹⁴, SR¹⁴, -CF₃,
 15 COR¹⁴, CO₂R¹⁴, CONR¹³R^{13a}, NHC(S)NR¹³R^{13a}, SO₂NR¹³R^{13a}, and SO₂R¹⁴;

R¹³, R^{13a} and R^{13b} are each independently selected from the group: H or methyl; and

R¹⁴ is independently selected from the group: H, methyl,
 20 phenyl, and benzyl.

11. A compound according to claim 1 wherein:

X is O or S;

R¹ is -NR³R^{3a}, -CF₃, C₁₋₄ alkyl substituted with 1-3 R⁴;

25 R⁴ is, at each occurrence, independently selected from the group: halo, -CN, NO₂, -NR⁹R^{9a}, NR⁹NR^{9a}R^{9b}, NR⁹C(O)OR¹⁰, NR⁹C(O)R¹⁰, =O, OR¹⁰, SR¹⁰, -CF₃, COR¹⁰, CO₂R¹⁰, CONR⁹R^{9a}, NHC(O)NR⁹R^{9a}, NHC(S)NR⁹R^{9a}, SO₂NR⁹R^{9a}, and SO₂R¹⁰;

30 R⁹ is, at each occurrence, independently selected from the group: H, C₁₋₄ alkyl, phenyl and benzyl;

5 R^{9a} is, at each occurrence, independently selected from the group: H, C₁₋₄ alkyl, phenyl and benzyl;
 R^{9b} is, at each occurrence, independently selected from the group: H, C₁₋₄ alkyl, phenyl and benzyl; or
 R⁹ and R^{9a}, together with the nitrogen atom to which they
 10 are attached, form a 5-7 membered heterocycle substituted with 0-3 R¹⁶;
 R¹⁶ is, at each occurrence, independently selected from the group consisting of: halo, -CN, NO₂, C₁₋₄ alkyl, C₁₋₄ haloalkyl, NR²⁰R^{20a}, NR^{20b}NR²⁰R^{20a}, NR²⁰C(O)OR²¹,
 15 NR²⁰C(O)R²¹, =O, OR²¹, SR²¹, COR²¹, CO₂R²¹, CONR²⁰R^{20a}, NHC(O)NR²⁰R^{20a}, NHC(S)NR²⁰R^{20a}, SO₂NR²⁰R^{20a}, and SO₂R²¹; and
 R²⁰, R^{20a}, and R^{20b} are, at each occurrence, independently selected from the group: H, C₁₋₄ alkyl, phenyl and
 20 benzyl.

12. A compound according to claim 1 wherein:
 X is O or S;
 R¹ is -NR³R^{3a}, -CF₃, C₁₋₄ alkyl substituted with 1-3 R⁴;
 25 R³ and R^{3a} are independently selected from the group: H, methyl, phenyl and benzyl;
 R⁴ is, at each occurrence, independently selected from the group: halo, -CN, NO₂, -NR⁹R^{9a}, NR⁹NR^{9a}R^{9b},
 NR⁹C(O)OR¹⁰, NR⁹C(O)R¹⁰, =O, OR¹⁰, SR¹⁰, -CF₃, COR¹⁰,
 30 CO₂R¹⁰, CONR⁹R^{9a}, NHC(O)NR⁹R^{9a}, NHC(S)NR⁹R^{9a}, SO₂NR⁹R^{9a}, SO₂R¹⁰, C₃₋₁₀ carbocycle substituted with

5 0-5 R¹¹, and 5-10 membered heterocycle substituted with
 0-3 R¹¹;

R⁹ is, at each occurrence, independently selected from the
 group: H, C₁₋₄ alkyl, phenyl and benzyl;

10 R^{9a} is, at each occurrence, independently selected from the
 group: H, C₁₋₄ alkyl, phenyl and benzyl;

R^{9b} is, at each occurrence, independently selected from the
 group: H, C₁₋₄ alkyl, phenyl and benzyl;

R¹⁰ is, at each occurrence, independently selected from the
 group: H, C₁₋₄ alkyl, phenyl, benzyl; and

15 R¹¹ is, at each occurrence, independently selected from the
 group consisting of: selected from the group: halo, -
 CN, NO₂, C₁₋₄ alkyl, C₁₋₄ haloalkyl, NR¹⁸R^{18a},
 NR¹⁸NR^{18a}R^{18b}, NR¹⁸C(O)OR¹⁷, NR¹⁸C(O)R¹⁷, =O, OR¹⁷,
 SR¹⁷, COR¹⁷, CO₂R¹⁷, CONR¹⁸R^{18a}, NHC(O)NR¹⁸R^{18a},
 NHC(S)NR¹⁸R^{18a}, SO₂NR¹⁸R^{18a}, SO₂R¹⁷, C₃₋₁₀ carbocycle
 substituted with 0-5 R¹⁹, and 5-10 membered heterocycle
 substituted with 0-3 R¹⁹.

13. A compound according to claim 1 wherein:

25 R² is C₁₋₄ alkyl substituted with 0-3 R⁷, C₂₋₄ alkenyl
 substituted with 0-3 R⁷, C₂₋₄ alkynyl substituted with
 0-3 R⁷, -CF₃; C₃₋₆ carbocycle substituted with 0-5 R⁸,
 or 3-7 membered heterocycle substituted with 0-5 R⁸.

30 14. A compound according to claim 1 wherein:

- 5 R^2 is C_{1-4} alkyl substituted with 0-3 R^7 , C_{2-4} alkenyl substituted with 0-3 R^7 , C_{2-4} alkynyl substituted with 0-3 R^7 , $-CF_3$, C_{3-6} carbocycle substituted with 0-5 R^8 , or 5-7 membered heterocycle substituted with 0-5 R^8 .
- 10 15. A compound according to claim 1 wherein:
 R^2 is C_{3-6} saturated carbocycle substituted with 0-5 R^8 , or 5-7 membered saturated heterocycle substituted with 0-5 R^8 .
- 15 16. A compound according to claim 1 wherein:
 R^2 is C_{5-6} partially saturated carbocycle substituted with 0-5 R^8 , or 5-7 membered partially saturated heterocycle substituted with 0-5 R^8 .
- 20 17. A compound according to claim 1 wherein:
 R^2 is phenyl substituted with 0-5 R^8 , naphthyl substituted with 0-5 R^8 or or 5-6 membered aromatic heterocycle substituted with 0-5 R^8 .
- 25 18. A compound according to claim 1 wherein:
 R^2 is phenyl substituted with 0-3 R^8 , naphthyl substituted with 0-3 R^8 or or 5-6 membered aromatic heterocycle substituted with 0-3 R^8 .
- 30 19. A compound according to claim 1 wherein:

5 R^2 is C₃₋₆ carbocycle substituted with 0-5 R^8 , or 5-7
membered heterocycle substituted with 0-5 R^8 ;

R^8 is, at each occurrence, independently selected from the
group: halo, -CN, NO₂, C₁₋₄ alkyl, C₁₋₄ haloalkyl,
10 NR¹³R^{13a}, NR¹³NR^{13a}R^{13b}, NR¹³C(O)OR¹⁴, NR¹³C(O)R¹⁴, =O,
OR¹⁴, SR¹⁴, -CF₃, COR¹⁴, CO₂R¹⁴, CONR¹³R^{13a},
NHC(O)NR¹³R^{13a}, NHC(S)NR¹³R^{13a}, SO₂NR¹³R^{13a}, and
SO₂R¹⁴, or when two R^{8s} are attached to two adjacent
carbon atoms, the two R^{8s} may combine to form -OCH₂O-
15 or -OCH₂CH₂O-; and

R¹³ R^{13a}, and R^{13b} are, at each occurrence,
independently selected from the group: H, C₁₋₄ alkyl,
phenyl and benzyl; or

R¹³ and R^{13a}, together with the nitrogen atom to which they
20 are attached, form a 5-7 membered heterocycle
substituted with 0-3 R¹⁶.

20. A compound according to claim 1 wherein:

R^2 is C₃₋₆ carbocycle substituted with 0-5 R^8 , or 5-7
25 membered heterocycle substituted with 0-5 R^8 ;

R^8 is, at each occurrence, independently selected from the
group: halo, -CN, NO₂, C₁₋₄ alkyl, C₁₋₄ haloalkyl,
NR¹³R^{13a}, NR¹³NR^{13a}R^{13b}, NR¹³C(O)OR¹⁴, NR¹³C(O)R¹⁴, =O,
OR¹⁴, SR¹⁴, -CF₃, COR¹⁴, CO₂R¹⁴, CONR¹³R^{13a},
30 NHC(O)NR¹³R^{13a}, NHC(S)NR¹³R^{13a}, SO₂NR¹³R^{13a}, SO₂R¹⁴,
C₃₋₁₀ carbocycle substituted with 0-5 R¹⁵, and 5-10

- 5 membered heterocycle substituted with 0-3 R^{15} , or when
 two R^{8s} are attached to two adjacent carbon atoms, the
 two R^{8s} may combine to form $-OCH_2O-$ or $-OCH_2CH_2O-$;
- 13 R^{13a} , and R^{13b} are, at each occurrence, independently
 selected from the group: H, C₁₋₄ alkyl, phenyl and
 10 benzyl; and
- R^{15} is, at each occurrence, independently selected from the
 group consisting of: halo, $-CN$, NO_2 , C₁₋₄ alkyl, C₁₋₄
 haloalkyl, $NR^{20}R^{20a}$, $NR^{20b}NR^{20}R^{20a}$, $NR^{20}C(O)OR^{21}$,
 $NR^{20}C(O)R^{21}$, $=O$, OR^{21} , SR^{21} , COR^{21} , CO_2R^{21} , $CONR^{20}R^{20a}$,
 15 $NHC(O)NR^{20}R^{20a}$, $NHC(S)NR^{20}R^{20a}$, $SO_2NR^{20}R^{20a}$, and
 SO_2R^{21} , or when two $R^{15}s$ are attached to two adjacent
 carbon atoms, the two $R^{15}s$ may combine to form $-OCH_2O-$
 or $-OCH_2CH_2O-$.
- 20 21. A compound according to claim 1 wherein:
 X is O or S;
 R^1 is $-NR^3R^{3a}$, $-CF_3$, C₁₋₄ alkyl substituted with 1-3 R^4 ,
 C₂₋₄ alkenyl substituted with 0-3 R^4 , C₂₋₄ alkynyl
 substituted with 0-3 R^4 , C₃₋₆ carbocycle substituted
 25 with 0-5 R^6 , or 5-7 membered heterocycle substituted
 with 0-3 R^6 ; and
- R^2 is C₁₋₄ alkyl substituted with 0-3 R^7 , C₂₋₄ alkenyl
 substituted with 0-3 R^7 , C₂₋₄ alkynyl substituted with
 0-3 R^7 , $-CF_3$, C₃₋₆ carbocycle substituted with 0-5 R^8 ,
 30 or 5-7 membered heterocycle substituted with 0-5 R^8 .

5 22. A compound according to claim 1 wherein:

R^1 is phenyl substituted with 1-5 R^6 , naphthyl substituted with 0-5 R^6 , or 5-6 membered aromatic heterocycle substituted with 0-3 R^6 ;

R^2 is C₃₋₆ carbocycle substituted with 0-5 R^8 , or 5-7

10 membered heterocycle substituted with 0-5 R^8 ;

R^8 is, at each occurrence, independently selected from the group: halo, -CN, NO₂, C₁₋₄ alkyl, C₁₋₄ haloalkyl, NR¹³R^{13a}, NR¹³NR^{13a}R^{13b}, NR¹³C(O)OR¹⁴, NR¹³C(O)R¹⁴, =O, OR¹⁴, SR¹⁴, -CF₃, COR¹⁴, CO₂R¹⁴, CONR¹³R^{13a},
15 NHC(O)NR¹³R^{13a}, NHC(S)NR¹³R^{13a}, SO₂NR¹³R^{13a}, and SO₂R¹⁴, or when two R^{8s} are attached to two adjacent carbon atoms, the two R^{8s} may combine to form -OCH₂O- or -OCH₂CH₂O-; and

R¹³ R^{13a}, and R^{13b} are, at each occurrence,

20 independently selected from the group: H, C₁₋₄ alkyl, phenyl and benzyl; or

R¹³ and R^{13a}, together with the nitrogen atom to which they are attached, form a 5-7 membered heterocycle substituted with 0-3 R^{16} .

25

23. A compound according to claim 1 wherein:

X is O or S;

R^1 is -NR³R^{3a}, -CF₃, C₁₋₄ alkyl substituted with 1-3 R^4 ;

R^2 is C₁₋₄ alkyl substituted with 0-3 R^7 , C₂₋₄ alkenyl

30 substituted with 0-3 R^7 , C₂₋₄ alkynyl substituted with

5 0-3 R⁷, -CF₃, C₃₋₆ carbocycle substituted with 0-5 R⁸,
or 5-7 membered heterocycle substituted with 0-5 R⁸;
R⁴ is, at each occurrence, independently selected from the
group: halo, -CN, NO₂, -NR⁹R^{9a}, NR⁹NR^{9a}R^{9b},
NR⁹C(O)OR¹⁰, NR⁹C(O)R¹⁰, =O, OR¹⁰, SR¹⁰, -CF₃, COR¹⁰,
10 CO₂R¹⁰, CONR⁹R^{9a}, NHC(O)NR⁹R^{9a}, NHC(S)NR⁹R^{9a},
SO₂NR⁹R^{9a}, and SO₂R¹⁰;
R⁹ is, at each occurrence, independently selected from the
group: H, C₁₋₄ alkyl, phenyl and benzyl;
R^{9a} is, at each occurrence, independently selected from the
15 group: H, C₁₋₄ alkyl, phenyl and benzyl;
R^{9b} is, at each occurrence, independently selected from the
group: H, C₁₋₄ alkyl, phenyl and benzyl; or
R⁹ and R^{9a}, together with the nitrogen atom to which they
are attached, form a 5-7 membered heterocycle
20 substituted with 0-3 R¹⁶;
R¹⁶ is, at each occurrence, independently selected from the
group consisting of: halo, -CN, NO₂, C₁₋₄ alkyl, C₁₋₄
haloalkyl, NR²⁰R^{20a}, NR^{20b}NR²⁰R^{20a}, NR²⁰C(O)OR²¹,
NR²⁰C(O)R²¹, =O, OR²¹, SR²¹, COR²¹, CO₂R²¹, CONR²⁰R^{20a},
25 NHC(O)NR²⁰R^{20a}, NHC(S)NR²⁰R^{20a}, SO₂NR²⁰R^{20a}, and
SO₂R²¹; and
R²⁰, R^{20a}, and R^{20b} are, at each occurrence, independently
selected from the group: H, C₁₋₄ alkyl, phenyl and
benzyl.

30

5 24. A compound according to claim 1 selected from the group:

3-(4-methoxyphenyl)-5-(2-(3,5-dimethoxybenzoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

10 3-(4-methoxyphenyl)-5-(2-isonicotinoyl
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-nicotinoylhydrazinecarbox
amido)indeno[1,2-c]pyrazol-4-one;

15 3-(4-methoxyphenyl)-5-(2-(3,4-dihydroxybenzoyl)hydrazine
carboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-(4-hydroxybenzoyl)hydrazine
20 carboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-(3-aminobenzoyl)hydrazine
carboxamido)indeno[1,2-c]pyrazol-4-one;

25 3-(4-methoxyphenyl)-5-(2-(4-aminobenzoyl)hydrazine
carboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-(2-aminobenzoyl)hydrazine
carboxamido)indeno[1,2-c]pyrazol-4-one;

30 3-(4-methoxyphenyl)-5-(2-(4-N,N-dimethylaminobenzoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-methoxybenzoylhydrazine
35 carboxamido)indeno[1,2-c]pyrazol-4-one;

- 5 3-(4-methoxyphenyl)-5-(2-(2-hydroxybenzoyl)hydrazine
carboxamido)indeno[1,2-c]pyrazol-4-one; and
- 3-(4-methoxyphenyl)-5-(2-(3,5-diaminobenzoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;
- 10 3-(4-methoxyphenyl)-5-(2-(1-naphthoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;
- 3-(4-methoxyphenyl)-5-(2-amido
15 hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;
- 3-(4-methoxyphenyl)-5-(2-phenylamido
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;
- 20 3-(4-methoxyphenyl)-5-(2-(4-methylbenzoyl
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;
- 3-(4-methoxyphenyl)-5-(2-(2-naphthoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;
- 25 3-(4-methoxyphenyl)-5-(2-(3-(4-hydroxyphenyl)propionyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;
- 3-(4-methoxyphenyl)-5-(2-(4-methoxybenzoyl)
30 hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;
- 3-(4-methoxyphenyl)-5-(2-(3-nitrobenzoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;
- 35 3-(4-methoxyphenyl)-5-(2-(3-nitrobenzoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

5

3-(4-methoxyphenyl)-5-(2-(2-thienoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-(3-methylbenzoyl)
10 hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-(3-amino-4-hydroxybenzoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

15 3-(4-methoxyphenyl)-5-(2-(2,5-dichlorobenzoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-methoxyphenyl)-5-(2-(3,4-dihydroxybenzoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

20

3-(4-piperazinyphenyl)-5-(2-(nicotinoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-(4-methylpiperazinyphenyl)-5-(2-(nicotinoyl)
25 hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

3-(4-(4-methylpiperazinyphenyl)-5-(2-(isonicotinoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one;

30 3-(4-piperazinyphenyl)-5-(2-(isonicotinoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one; and

3-(4-piperazinyphenyl)-5-(2-(3,5-dimethoxybenzoyl)
hydrazinecarboxamido)indeno[1,2-c]pyrazol-4-one; or

5 a pharmaceutically acceptable salt form thereof, a
pharmaceutically acceptable prodrug form thereof, an N-oxide
form thereof, or a stereoisomer thereof.

25. A pharmaceutical composition, comprising: a
10 pharmaceutically acceptable carrier and a therapeutically
effective amount of a compound of claim 1.

26. A pharmaceutical composition, comprising a
pharmaceutically acceptable carrier, a compound according
15 to claim 1 or a pharmaceutically acceptable salt or prodrug
form thereof, and a cytostatic or cytotoxic agent.

27. A method of treating a cell proliferative disease
associated with CDK activity in a patient in need
20 thereof, comprising administering to said patient a
pharmaceutically effective amount of a compound according to
claim 1, or a pharmaceutically acceptable salt or prodrug
form thereof, wherein the proliferative diseases is selected
from the group consisting of: Alzheimer's disease, viral
25 infections, auto-immune diseases, fungal disease, cancer,
psoriasis, vascular smooth cell proliferation associated
with atherosclerosis, pulmonary fibrosis, arthritis
glomerulonephritis, neurodegenerative disorders and post-
surgical stenosis and restenosis.

30
28. A method of treating cancer associated with CDK
activity in a patient in need thereof, comprising
administering to said patient a pharmaceutically effective
amount of a compound according to claim 1, or a
35 pharmaceutically acceptable salt or prodrug form thereof,
wherein the cancer is selected from the group consisting of:
carcinoma such as bladder, breast, colon, kidney, liver,
lung, including small cell lung cancer, esophagus, gall-
bladder, ovary, pancreas, stomach, cervix, thyroid,

5 prostate, and skin, including squamous cell carcinoma;
hematopoietic tumors of lymphoid lineage, including
leukemia, acute lymphocytic leukemia, acute lymphoblastic
leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's
lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and
10 Burkett's lymphoma; hematopoietic tumors of myeloid lineage,
including acute and chronic myelogenous leukemias,
myelodysplastic syndrome and promyelocytic leukemia; tumors
of mesenchymal origin, including fibrosarcoma and
rhabdomyosarcoma; tumors of the central and peripheral
15 nervous system, including astrocytoma, neuroblastoma, glioma
and schwannomas; other tumors, including melanoma, seminoma,
teratocarcinoma, osteosarcoma, xenoderoma pigmentosum,
keratoctanthoma, thyroid follicular cancer and Kaposi's
sarcoma.

20

29. A method of treating a disease associated with
apoptosis in a patient in need thereof, comprising
administrering to said patient a pharmaceutically effective
amount of a compound according to claim 1, or a
25 pharmaceutically acceptable salt or prodrug form thereof,
wherein the disease associated with apoptosis is selected
from the group consisting of: cancer, viral infections,
autoimmune diseases and neurodegenerative disorder.

30 30. A method of inhibiting tumor angiogenesis and
metastasis in a patient in need thereof, comprising
administrering to said patient a pharmaceutically effective
amount of a compound according to claim 1, or a
pharmaceutically acceptable salt or prodrug form thereof.

35

31. A method of modulating the level of cellular RNA and
DNA synthesis in a patient in need thereof, comprising
administering to said patient a CDK inhibitory effective

5 amount of a compound according to claim 1, or a
pharmaceutically acceptable salt or prodrug form thereof.

32. A method of treating viral infections in a patient in
need thereof, comprising administering to said patient a CDK
10 inhibitory effective amount of a compound according to claim
1, or a pharmaceutically acceptable salt or prodrug form
thereof, wherein the viral infections is selected from the
group consisting of HIV, human papilloma virus, herpesvirus,
poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus.

15 33. A method of chemopreventing cancer in a patient,
comprising administering to said patient in need thereof, a
CDK inhibitory effective amount of a compound according to
claim 1, or a pharmaceutically acceptable salt or prodrug
20 form thereof.

34. A method of inhibiting CDK activity comprising
combining an effective amount of a compound according to
claim 1, with a composition containing CDK.

25 35. A method of treating cancer associated with CDK
activity in a patient in need thereof, comprising
administering to said patient a pharmaceutically effective
amount of a compound according to claim 1, or a
30 pharmaceutically acceptable salt or prodrug form thereof,
in combination (administered together or sequentially) with
known anti-cancer treatments such as radiation therapy or
with cytostatic or cytotoxic agents, wherein such agents are
selected from the group consisting of: DNA interactive
35 agents, such as cisplatin or doxorubicin; topoisomerase II
inhibitors, such as etoposide; topoisomerase I inhibitors
such as CPT-11 or topotecan; tubulin interacting agents,
such as paclitaxel, docetaxel or the epothilones; hormonal
agents, such as tamoxifen; thymidilate synthase inhibitors,

5 such as 5-fluorouracil; and anti-metabolites, such as methotrexate.

36. A method treating cell proliferative diseases associated with CDK activity in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof, in combination (administered together or sequentially) with known anti-proliferating agents selected from the group consisting of: altretamine, busulfan, chlorambucil, cyclophosphamide, ifosfamide, mechlorethamine, melphalan, thiotepa, cladribine, fluorouracil, floxuridine, gemcitabine, thioguanine, pentostatin, methotrexate, 6-mercaptapurine, cytarabine, carmustine, lomustine, streptozotocin, carboplatin, cisplatin, oxaliplatin, iproplatin, tetraplatin, lobaplatin, JM216, JM335, fludarabine, aminoglutethimide, flutamide, goserelin, leuprolide, megestrol acetate, cyproterone acetate, tamoxifen, anastrozole, bicalutamide, dexamethasone, diethylstilbestrol, prednisone, bleomycin, dactinomycin, daunorubicin, doxorubicin, idarubicin, mitoxantrone, losoxantrone, mitomycin-c, plicamycin, paclitaxel, docetaxel, CPT-11, epothilones, topotecan, irinotecan, 9-amino camptothecin, 9-nitro camptothecin, GS-211, etoposide, teniposide, vinblastine, vincristine, vinorelbine, procarbazine, asparaginase, pegaspargase, methotrexate, octreotide, estramustine, and hydroxyurea.

37. A method of inhibiting CDK1 activity, comprising administering to a patient in need thereof an effective CDK1 inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.

- 5 38. A method of inhibiting CDK2 activity, comprising
administering to a patient in need thereof an effective CDK2
inhibitory amount of a compound according to claim 1, or a
pharmaceutically acceptable salt or prodrug form thereof.
- 10 39. A method of inhibiting CDK3 activity, comprising
administering to a patient in need thereof an effective CDK3
inhibitory amount of a compound according to claim 1, or a
pharmaceutically acceptable salt or prodrug form thereof.
- 15 40. A method of inhibiting CDK4 activity, comprising
administering to a patient in need thereof an effective CDK4
inhibitory amount of a compound according to claim 1, or a
pharmaceutically acceptable salt or prodrug form thereof.
- 20 41. A method of inhibiting CDK5 activity, comprising
administering to a patient in need thereof an effective CDK5
inhibitory amount of a compound according to claim 1, or a
pharmaceutically acceptable salt or prodrug form thereof.
- 25 42. A method of inhibiting CDK6 activity, comprising
administering to a patient in need thereof an effective CDK6
inhibitory amount of a compound according to claim 1, or a
pharmaceutically acceptable salt or prodrug form thereof.
- 30 43. A method of inhibiting CDK7 activity, comprising
administering to a patient in need thereof an effective CDK7
inhibitory amount of a compound according to claim 1, or a
pharmaceutically acceptable salt or prodrug form thereof.
- 35 44. A method of inhibiting CDK8 activity, comprising
administering to a patient in need thereof, an effective CDK8
inhibitory amount of a compound according to claim 1, or a
pharmaceutically acceptable salt or prodrug form thereof.

- 5 45. A method of inhibiting CDK9 activity, comprising
administering to a patient in need thereof an effective CDK9
inhibitory amount of a compound according to claim 1, or a
pharmaceutically acceptable salt or prodrug form thereof.
- 10 46. A pharmaceutical kit for treating a cell proliferative
disease associated with CDK activity, said kit comprising a
plurality of separate containers, wherein at least one of
said containers contains a compound according to claim 1, or
a pharmaceutically acceptable salt or prodrug form thereof,
15 and at least another of said containers contains one or more
compounds selected from the group consisting of cytostatic
or cytotoxic agents, such as for example, but not limited
to, DNA interactive agents, such as carboplatin, cisplatin
or doxorubicin; topoisomerase II inhibitors, such as
20 etoposide; topoisomerase I inhibitors such as CPT-11 or
topotecan; tubulin interacting agents, such as paclitaxel,
taxane, docetaxel or the epothilones; hormonal agents, such
as tamoxifen; thymidilate synthase inhibitors, such as 5-
fluorouracil; and anti-metabolites, such as methotrexate,
25 and said containers optionally contain a pharmaceutical
carrier, which kit may be effectively utilized for carrying
out combination therapies according to the invention.

INTERNATIONAL SEARCH REPORT

Internat Application No

PCT/JP 00/28952

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D231/54 C07D401/12 C07D409/12 A61K31/416 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 54308 A (DU PONT PHARM CO) 28 October 1999 (1999-10-28) compounds LXIV, CIV - CXI, CXIII, CXIV, CL page 1, line 10 - line 15; claims 1,7 -----	1-46

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

8 June 2001

Date of mailing of the international search report

19/06/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Seymour, L

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

The present claims do not meet the requirements of Article 6 PCT in that the matter for which protection is sought is not clearly defined. The functional term "prodrug" does not enable the skilled person to determine which technical features are necessary to perform the stated function. It is thus unclear which specific compounds fall within the scope of said claim. A lack of clarity within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search does not include prodrugs of the compounds of formula I.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International

Application No

PCT/JP 00/28952

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9954308 A	28-10-1999	AU 3654899 A EP 1071668 A	08-11-1999 31-01-2001
<hr/>			